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標 D N A或 R N A是互補的，因而阻止轉錄及 /或轉譯 。最近，利用反有意 
義治療針對由致癌基因 B C L - 2引起的未期癌症，已在人體進行臨床測試， 
並且有令人鼓舞的成效。 
我們的實驗曾利用整條對0化1-1 m R N A 的 反 有 意 義 R N A ， 透 過 載 體 應 
用於人類血癌 H L - 6 0細胞，發現可抑制達 5 0至 6 0 %的細胞增生。同時，利 
用RNA印跡（>^011匕6皿5101)，亦顯示Glut-1 m R N A數量減低。 
目前，在反有意義的研究及其抗癌功能的發展中，最大的困難是如何使 




高溫效應於 4 3 ° C對細胞攝取此〇 D N的反應。是次研究測試了四種不同的細 














i ^ $ f t S f u t T k 0 ^ ^ - 5 )兩者同時結合在 M C F - 7細胞有加成 =， = 
,^,：：.^ ； effect)。五小時 43。C 的高溫效應結合 8 一 的 antisense Glut-1 或 
= - T S l J i A ^ i _ M C F - 7癌細胞的增生分別達 6 7 %及 6 3 %。 
CONTENTS. 
A CKNO WLED GMENTS p.7 
ABSTRACT p.8-I0 
Chapter 1: Introduction. p.11-44 
1.1) Glucose transporters 
1.2) Glucose transporters and cancers 
1.3) Antisense strategies 
1.4) Cellular uptake of oligonucleotides 
1.5) Hyperthermia and combined treatments 
Chapter 2: Materials and methods. p.45-60 
2.1) Materials: 
2.1a) Cell lines and culture media 
2.1b) Oligonucleotides synthesis 
2.1c) Chemicals 
2.2) Methods: 
2.2a) Oligonucleotide design 
2.2b) Oligonucleotide treatment 
2.2c) Flow cytometry 
2.2d) Confocal microscopy 
2.2e) M T T assay for cytotoxicity or cell proliferation 
Chapter 3: p.61-85 
Cellular uptake ofoligonucleotide spontaneously and Lipofectin-aided: 
3.1) Introduction 
3.2) Flow cytometric studies 
3.3) Confocal microscopic studies 
3.4) Cytotoxic effect ofLipofectin alone on MCF-7 cells 
3.5) Discussion 
Chapter 4: 
Hyperthermia can enhance oligonucleotide uptake. 
p.86-118 
4.1) Introduction 
4.2) Flow cytometric studies 
4.3) Confocal microscopic smdies 
4.4) Cytotoxic effect ofhyperthermia on MCF-7 cells 
4.5) FITC-ODN uptake in survival cells by propidium iodide (PI) 
exclusion method for hyperthermia 
4.6) Discussion 
Chapter 5: The antiproliferative effects of antisense molecules against Glut-1 
and 5 on MCF-7 cells transfected by Lipofectin: p. 119-146 
5.1) Introduction 
5.2) The growth curve ofMCF-7 cells 
5.3) The calibration ofMTT assay 
5.4) The effect of antisense Glut-1 concentration without Lipofectin on 
MCF-7 cells 
5.5) The effect of antisense Glut-1 concentration with Lipofectin on 
MCF-7 cells 
5.6) The effect of antisense Glut-5 concentration without Lipofectin on 
MCF-7 cells 
5.7) The effect of antisense Glut-5 concentration with Lipofectin on 
MCF-7cells 
5.8) The effect of transfection time of antisense Glut-1 on MCF-7 cells 
5.9) The effect of transfection time of antisense Glut-5 on MCF-7 cells 
5.10) The effect of transfection time of antisense Glut-5 for higher 
concentration on MCF-7 cells 
5.11) The effect of antisense Glut-1 to Lipofectin (w/w) ratio on MCF-7 
cells 
5.12) The effect of antisense Glut-1 to Lipofection (w/w) ratio for 
higher transfection time on MCF-7 cells 
5.13) The effect of antisense Glut-5 to Lipofectin (w/w) ratio on MCF-7 
cells 
5.14) Discussion 
Chapter 6: Combined treatments: p. 147-162 
6.1) Introduction 
6.2) The effect of combined treatment of antisense Glut-1 combined 
with antisense Glut-5 on MCF-7 cells 
6.3) The chronic effect ofhyperthermia for 5 hours on MCF-7 cells 
6.4) The effect of combined treatment between antisense Glut-1 and 
hyperthermia on MCF-7 cells 
6.5) The net effect of antisense Glut-1 in combined treatment between 
hyperthermia and antisense Glut-1 on MCF-7 cells 
6.6) The effect of combined treatment between antisense Glut-5 and 
hyperthermia on MCF-7 cells 
6.7) The net effect of antisense Glut-5 in combined treatment between 
hyperthermia and antisense Glut-5 on MCF-7 cells 
6.8) Discussion 
Chapter 7: Discussion. 
Chapter 8: References: 
p.163-173 
p.174-181 
A CKNO WLED GMENTS: 
To my supervisors, Prof. K. P. Fung and Prof. C. Y. Lee, without their 
guidance and supervision with future perspective ideas, the thesis will not be 
performed by me，at this time. 
For the science and our future. 
Abstract: 
Cellular glucose uptake is mediated by facilitative glucose transporters 
(Glut). These transporters show tissue-specific distribution, but overexpression of 
isoforms type 1 (Glut-1) and type 3 (Glut-3) have been reported in many kinds of 
human cancers. Moreover, some tumors deviate from the normal tissue in 
distribution of glucose transporters, e.g. Glut-5 which is absent in normal breast 
tissue is expressed in human breast cancer. Since cancer cells are under rapid 
growing, extra energy in the form of glucose is required. Some previous studies 
have targeted on the inhibition of glucose transport to suppress the proliferation of 
tumor cells. However, inhibitors of glucose uptake have severe side effects on 
patients and their action is also not specific. 
Antisense strategy is a developing novel technique to inhibit gene expression 
specifically. The strategy makes use of modified antisense molecules, mostly 
DNA, which has a sequence complementary to part of the target D N A or mRNA, 
to prevent translation and/or transcription. Recently, human clinical trial of 
antisense treatment against oncogene BCL-2 on late stage cancer is in progress 
and the results in the early report are encouraging. In our previous studies, full 
length antisense R N A against Glut-1 m R N A was applied in HL-60 cells by 
expression vector. The results show that antisense R N A of Glut-1 inhibited the 
proliferation ofHL-60 cells by 50-60 % and the m R N A expression of Glut-1 gene 
was suppressed as detected by Northern hybridization. 
Cellular uptake of antisense oligodeoxynucleotide (ODN) is one of the major 
problems in antisense research and development into cancer therapy. Besides, it 
has been reported that hyperthermia can enhance the cellular uptake of antitumor 
drugs, such as，doxorubicin in vitro and in vivo. In first part of the present 
investigation, we used Fluorescein (FITC) labeled phosphorothioate 15 bases 
ODN: 5'- Fluoro-TTG CTC CAT G C T T G C —3,, to study the effect of 
hyperthermia (HT) at 43°C, on cellular uptake of ODN. Four cell lines, namely, 
MCF-7, MDA-MB-231, Caco-2 and HepG-2, were used. The result was also 
compared with lipofectin (DOTMA) - aided transfection, which was found as a 
means to increase the uptake of 〇DN by other researchers. Flow cytometry and 
confocal microscopy were applied to study the uptake and distribution of O D N in 
MCF-7 cells respectively. By flow cytometry, we found that hyperthermia on 
43°C for 15 hours could increase the uptake by 3-fold on average. Hyperthermia 
enhanced cellular uptake was time-and concentration-dependent. In addition, 
Lipofectin could enhance the uptake for more than 34-fold on average in 
experiment when MCF-7 cells were treated with 0.5 ^ iM O D N s with 1 to 10 O D N 
to Lipofectin w/w ratio by 15 hours transfection time. By confocal microscopy, it 
was found that the O D N were mostly located at the cytoplasm in cells treated with 
hyperthermia and with Lipofectin-aided transfection. 
It is found that hyperthermia could enhance the cellular uptake of antisense 
molecules in vitro. The probable anti-proliferative effect of combined treatment 
between hyperthermia and antisense phosphorothioated oligodeoxynucleotide 
against glucose transporters on MCF-7 cells were further studied. The combined 
effect was also compared with Lipofectin-aided antisense against Gluts. The 
results show that the combined effect of hyperthermia and antisense was additive 
for both Glut-1 and Glut-5. The antiproliferative effects for hyperthermia at 43°C 
for 5 hours plus 8 ^ iM of antisense Glut-1 and Glut-5 on MCF-7 cells were 67 % 
and 63 % respectively. 
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1.1) Glucose transporters 
The cell is surrounded by a sheet of membrane called plasma membrane 
which is basically composed of phospholipid (Figure 1.1). Any molecule in large 
size or hydrophilic in nature cannot pass through this membrane barrier into the 
cellular environment. As a result, a kind of transporter protein for glucose is 
developed to carry out the function of glucose uptake. This protein is named 
glucose transporter. 
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Glucose transporter families 
In mammalian cell systems, there are two glucose transporter families. The 
first one is Na+-dependent glucose co-transporter (SGLT family). This kind of 
glucose transporter is an active transporter that energy in form of ATP must be 
supplied. The Na+-dependent glucose co-transporter is mainly distributed at small 
intestine and kidney with the dependence of Na+ / K+ -ATPase which hydrolyses 
ATP and actively absorbs glucose against its concentration gradient (Takata, 
1996). The functions are active absorption and reabsorption in small intestine and 
kidney respectively. The second kind of glucose transporter is the facilitative 
glucose transporter family. This transporter transports glucose down its 
concentration gradient in a stereospecific manner and it requires no chemical 
energy. 
The mechanism of facilitative glucose transporter 
It is suggested that there are four steps involved when a glucose molecule 
‘enters into a cell. Firstly, the glucose molecule binds to the outward facing 
binding site of the glucose transporter protein. Secondly, the glucose transporter 
protein changes its conformation, such that the bound glucose molecule faces the 
intracellular compartments. Thirdly, the glucose is released into the cytoplasm of 
the cell as the change in conformation of glucose transporter protein induced by 
glucose molecule reduced the binding affinity. Finally, the glucose transporter 
protein changes the conformation back to initial stage that the glucose binding site 
1 2 
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is facing outward and is ready for the second round of glucose transport (Lienhard 
et, al, 1992). 
In this thesis, only facilitative glucose transporters will be studied and 
discussed, since only this family is involved in cancer cell development. Glucose 
transporter family has seven isoforms. In these seven isoforms, six members (Glut 
1-5 and 7) are expressed proteins and the Glut 6 is a pseudogene which is not 
expressed. Different forms of glucose transporters show structure similarity and 
tissue-specific distribution with varied kinetic and biochemical properties. 
i) The structure of glucose transporters: 
The molecular structure of glucose transporters 
The glucose transporter protein has 12 transmembrane spanning helices, 
both N- and C-termini are orientated at the cytoplasm. There are large loops 
between helices 1 and 2, and between 6 and 7. The large loop between helices 6 
and 7 divides the structure into two halves, the N-terminal domain and the C-
terminal domain. 
The loops between the remainder of the helices at the cytoplasmic surfaces 
are very short and the length of these loops that are about 8-12 residues is a 
conserved feature of the whole family (Bell et. al., 1993). These short loops place 
severe constraints on the possible tertiary structures and suggest very close 
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Figure 1.2: Predicted topology of Glut-1. The 12 predicted transmembrane helices are 
numbered 1 — 12. The single N-linked oligosaccharide is designated by C H O (Adapted from 
Mueckler. 1994). 
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packing of the helices at the inner surfaces of the membrane in each half of the 
protein. 
The length and sequence identities of the loops at the extracellular surface 
of these proteins are very varied but their lengths are generally longer than the 
loops at the cytoplasmic surfaces. This may potentially result in a less compact 
patching at the external surface for extracellular glucose to bind (Figure 1.2). 
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Transmembrane segments 3, 5，7, 8，and 11 contain many amino acid 
residues having hydroxyl (OH) and carbonylamino (CONH2) groups that can 
participate in hydrogen bonding with the hydroxyl groups on the glucose 
molecule (Lienhard et. aL, 1992). These segments may form the glucose binding 
site of the transporter protein. The polar groups in helices 7 and 8 are located on 
one surface of the a-helix and thus could form a polar channel through which the 
sugar is transported. A series of conserved threonine and asparagine residues are 
present in helix 8，these may constitute part of a hydrogen bonding channel 
accepting hexoses at the exofacial site and access to the inner binding site of the 
transporter. Release of the sugars at the inner site may be controlled by 
conformational changes occurring in helices 10 and 11, where highly conserved 
tryptophan and proline residues are present. Proline 383 and 385 are particularly 
important in facilitating an alternate opening and closing of the external site of the 
glucose transporters (Gould et. al., 1990) (Figure 1.2). 
Moreover, there are clusters of aromatic residues in helix 11 and 12，that are 
close in proximity in the protein. These planar interactions between the aromatic 
side chains of these amino acids may stabilize the structure. The glycine and 
proline rich region in helix 10 is expected to provide considerable flexibility to 
this region. 
The amino acid sequences ofglucose transporter 1-5 
The amino acid sequences of glucose transporter (Glut) type 1 to 5 are shown 
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Figure 1.3: The amino acid sequences ofhuman facilitative glucose transporter (Glut) type 
to 5 (Adaptedfrom Mueckler, 1994). 
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in Figure 1.3, 
Human Glut 1-5 exhibit 39 - 65% sequence identity and 50 - 76% sequence 
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ii) The kinetic properties and tissue-specific distribution of 
glucose transporters: 
Facilitative glucose transporters (Glut) contain one pseudogene and 6 
expressed isoforms that show variation in kinetic properties and tissue-specific 
distribution (Table 1.1). As each tissue has its own glucose requirement, so 
different types of glucose transporters exist to meet their needs. Each glucose 
transporter is numbered in the time order of discovery, so glucose transporter 
type-1 is the first one being discovered. 
Glucose Transporters Major tissue distributions Km to 2-Deoxyglucose 
Glut-1 Brain, blood-tissue barrier, red 
blood cells, all tissues.  
7 m M 
Glut-2 Liver, pancreatic P cells, 
kidney and small intestine. 
11 — 1 6 m M 
(Low affinity) 
Glut-3 Widely distributed in human 
tissues; restricted in brain in 
other species.  
l - 2 m M 
(high affinity) 
Glut-4 Skeletal and cardiac muscles, 
adipose tissue.  
5 m M 
Glut-5 (fructose transporter) Small intestine Q'ejunum), 
testis.  
Very low affinity; 
For fructose: 6 m M 
Glut-6 — Pseudogene.  None  
Glut-7 Microsomal glucose transporter 
of liver.  
Not known 
Table 1.1: Tissue distribution and glucose affinity of the seven facilitative glucose transporters 
(Modified from Bell et.al., 1993). 
1 7 
Glucose transporter type-1 
Glucose transporter type-1 (Glut-1) is also named as erythrocyte glucose 
transporter because it is the major transporter in red blood cells. Moreover, Glut-1 
is also well distributed in all human tissues. It appears to mediate basal glucose 
uptake in most tissues. Its Km value to 2-deoxyglucose is 7 m M , therefore is able 
to transport glucose in relatively low concentration similar to the basal state. In 
addition, the brain vascular system or blood brain barrier expresses large amount 
of Glut-1 so as to ensure adequate amount of glucose is being transported to 
support the function of such vital organ as central nervous system (Table 1.1). 
Glucose transporter type-2 
In contrast, glucose transporter type-2 (Glut-2) has a very low affinity to 
glucose, its Km value to 2-deoxyglucose is 11 — 16 m M . It is well distributed in 
liver, pancreatic B cells and kidney. This is believed that Glut-2 acts as a glucose 
sensor as it transports glucose only when the glucose level is very high in the 
blood. Liver and pancreatic B cell are involved in glucose metabolism. When 
blood glucose level is higher than normal, pancreatic B cells release insulin into 
the blood stream, hepatic cells have insulin receptors linked to glycogen synthesis 
pathway that convert glucose to glycogen. This is to keep a constant blood 
glucose level (Table 1.1). 
Glucose transporter type-3 
Glucose transporter type-3 (Glut-3) shows very high affinity to glucose. Its 
1 8 
Km value to 2-deoxyglucose is about 1 - 2 m M . Human glucose transporter type-3 
is widely distributed in human tissues, especially in brain neurons. But in other 
species, such as，mouse, Glut-3 is restricted to nervous tissue. As brain is an 
important organ for most organisms, the expression of Glut-1 and Glut-3 can 
support the organ with the essential chemical energy. Moreover, since normal 
blood glucose level ranges from 4 to 8 m M , Glut-1 and Glut-3 can continually 
transport glucose at an essential constant rate (Table 1.1). 
Glucose transporter type-4 
Glucose transporter type-4 (Glut-4) is an insulin-dependent glucose 
transporter. It regulates the entry of glucose into insulin-sensitive cells, such as, 
skeletal muscle cells and adipose cells. The possible mechanism is believed as 
translocation of Glut-4 from the vesicles in the cytoplasm to the cell membrane 
(Figure 1.4). When the blood glucose level is abnormally high, pancreatic B cells 
release insulin, insulin acts on hepatic cells as mentioned and it also enhances the 
glucose uptake on skeletal muscle cells and adipose cells through Glut-4. Hence, a 
constant blood glucose level can be maintained. The Km value to 2-deoxyglucose 
is about 5 m M (Table 1.1). 
1 9 
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Sequestration and sorting 
Tubulo-vesicular structures Endosomes 
F igur e 1.4: Insulin regulation of Glut-4 translocation. Glut-4 is predominantly present in 
intracellular tubulo-vesicular structures in the absence of insulin. Upon insulin stimulation, 
exocytosis is increased and Glut-4 vesicles dock and fuse with the plasma membrane. Occluded 
and partially occluded structures in the plasma membrane may be responsible for slight 
discrepanies between the level of stimulation of glucose transporter activity and Glut-4 as detected 
by photolabelling (active and partially occluded forms) and by Westem blotting (active, partially 
occluded forms). Glut-4 is recycled in both the absence and the presence of insulin through 
clathrin-coated vesicles. Multiple Glut-4 amino acid sequences responsible for targeting and 
sorting may be recognized by mechanisms present in the plasma membrane, the endosome 
recycling system andA)r the tubulo-vesicular structures (Adaptedfrom Gould et. al., 1993). 
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Glucose transporter type-5 
Glucose transporter type-5 is a fructose transporter, which is mainly present 
in the jejunum of the small intestine as well as testis. It seems do not transport 2-
deoxyglucose (Bell et. al, 1993) while the Km value for fructose is about 6 m M 
(Table 1.1). As fruit contains large amount of fructose and human being is able to 
survive by just eating fruits, so human has Glut-5 at their gut to absorb this 
energy-containing chemical and to convert fructose to glucose inside the body. 
This is interesting that our sperm cells have Glut-5 but the reason is still need to 
be uncovered. 
Glucose transporter type-6 
Glucose transporter type-6 is not expressed in cellular level. It is a 
pseudogene-like sequence, this sequence was found to contain multiple stop 
codons and frameshifts and is unlikely to encode a functional glucose transporter. 
Glucose transporter type-7 
Little information is available for glucose transporter type-7 which is a new 
member recently discovered. This transporter is present in microsomes of the liver 
and is believed as microsomal glucose transporter. The possible function is to 
export glucose from gluconeogenesis and glycogenolysis in hepatic cells to 
bloodstream. The terminal step for both the two processes is the removal of 
phosphate from glucose-6-phosphate by a specific phosphatase, glucose-6-
phosphoatase. It is a multicomponent enzyme and is well established that the 
2 1 
glucose produced as a result of the action of this phosphatase is initially confined 
to the lumen of the endoplasmic reticulum. For the glucose synthesized to be 
exported from the liver, it must first cross the endoplasmic reticulum membrane. 
The work of Burchell and her colleagues has revealed that the mechanism by 
which glucose crosses the endoplasmic reticulum membrane is via a unique 
member of the facilitative glucose transporter, namely Glut-7 (Waddell et. al, 
1992). 
1.2) Glucose transporters and cancers 
The nature of cancer cells 
Cancer cells are cells unable to be regulated in proliferation. They undergo 
relatively fast and continuous growth. The change from normal cell to tumor cell 
is named tumorogenesis, which is due to mutation, either spontaneously or 
chemically induced. Together with AIDS, cancer is the top killer for human 
patients. 
The relationship between cancer cells and glucose transporters 
Most cancer cells exhibit higher rates of glucose uptake and metabolism 
compared with normal cells. The change in glucose transport is independent of 
growth rate but are transformation specific. Indeed, such an increase in glucose 
transport is one of the most characteristic biochemical markers of the transformed 
phenotype. The enhanced glucose utilization in tumor cells involves an increased 
2 2 
number of glucose transporters. Over-expression of Glut-1 and Glut-3 are 
responsible for the changes in tumor transformation (Yamamoto et. al, 1990), 
There are two convenient methods used to detect the expression of Gluts in 
protein levels. The first one is Westem blot analysis and the second one is the 
immunohistochemistry which can localize Glut protein on tissue. Both of the two 
methods use specific antibodies to detect the target protein. For Westem blot 
analysis, the radioactive isotope is labeled to the antibody, the first or the second 
antibody. For immunohistochemistry, fluorescent material, such as, FITC, is 
labeled to the antibody. So the fluorescence signals detected are correspond to the 
presence of the target protein. 
In addition, Northern blot analysis or RT-PCR is usually used to detect the 
glucose transporter in the m R N A level. 
These methods have been used to measure the expression of Glut in tumor 
cells. 
i) Over-expression of Glut-1 and cancers: 
By immunostaining, glucose transporter type-1 has been found to be over-
expressed in cells of tissues of human bladder cancer, breast cancer, colon cancer, 
kidney cancer, lung cancer, ovary cancer, pancreas cancer, uterus cancer and 
2 3 
stomach cancer (Younes et. al, 1996) (Table 1.2). 
Tissues  Diagnosis  Positive cases/Total  
Bladder Transitional cell carcinoma  3/3 
Brain  Normal  0/2 
Breast Normal Ws ^ 
Adenocarcinoma  5/11 
Colon Normal m 
Adenocarcinoma  JJ9  
Kidney Normal m 
Renal cell carcinoma  m  
Lung Normal m 
Carcinoma  11/14 
Ovary Normal m 
Carcinoma  ^  
Pancreas Normal 0?5 
Adenocarcinoma  10/26 
Uterus Normal W^ 
Adenocarcinoma  m  
Stomach Normal W^ 
Adenocarcinoma  m  
Table 1.2: Over-expression of Glut-1 in various human cancer tissues (Adapted from Younes et. 
al, 1996). 
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Figure 1.5: Expression of Glut-2 mRNA in human cancer of digestive system. Position of 
28S and 18S ribosomal RNA are indicated. Liver metastasis indicates liver metastasis of colon 
cancer (Adaptedfrom Yamamoto et. al., 1990). 
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ii) Over-expression of Glut-2 and cancers: 
From the result of Northern blot analysis by Yamamoto et. al. (1990)，the 
Glut-2 was found to be expressed in normal liver and it is over-expressed in 
hepatoma. The levels of Glut-2 m R N A in hepatoma are higher than those in 
normal liver (Figure 1.5). However, Glut-2 level remains unchanged in liver 
metastasis (Figure 1.5). 
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ii) Over-expression of Glut-2 and cancers: 
Human glucose transporter type-3 is also over-expressed in a number of 
tumor tissues. By Northern blot analysis, it has been found that gastric cancer, 
colon cancer, hepatoma and pancreatic cancer showed over-expression of Glut-3 
(Yamamoto et. al, 1990) (Figure 1.6). 
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F i g u r e 1 .6a: Expression o f Glut-3 m R N A m human cancer o f digestive system. Position of 
28S and 18S nbosomal R N A are indicated (Adaptedfrom Yamamoto et. al, 1990). 
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iii) Over-expression of Glut-5 and cancers: 
Human glucose transporter type-5 is over-expressed in breast cancer and it 
is absent in normal breast tissue (Zamora-Leon et. al, 1996). Moreover, human 
breast cancer cell lines MCF-7 and MDA-MB-231 were also found to over-
express Glut-5. When compared with glucose transporter-1 and 3, Glut-5 has 
lower affinity to glucose, it can also transport fructose into the cytoplasm. 
The human breast cancer cell lines, MCF-7 and MDA-MD-231, express 
three isoforms of facilitative glucose transporters. They are Glut-1, Glut-2 and 
Glut-5. Among them, Glut-1 and Glut-2 are present in both normal and breast 
tumor cells, but Glut-5 is expressed in human breast cancer and is absent from 
normal breast tissue. This over-expression of Glut-5 on breast tumor tissue which 
is absent in normal tissue can be used as a biomarker to diagnose breast tumor. 
In addition to breast tumor cells, human colon cancer cell line Caco-2 was 
also found to over-express Glut-5. The Glut-5 m R N A level is growth dependent, 
and it is detectable only in post-confluent differentiated cells (Mesonero et. al, 
1995). 
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Key of the project 
From the evidences above, it seems that cancer tissues over-express glucose 
transporters. It is therefore interesting to study whether the inhibition of Gluts 
overexpression by antisense strategies can lead to the inhibition of proliferation of 
tumor cells. Hopefully, this idea could produce some suggestions to the 
development of more effective cancer therapy. 
As antisense oligodeoxynucleotides against oncogenes, the logic of the 
present project is based on an assumption that tumor cells will be affected more 
than normal tissues. It is because tumor cells are rapidly dividing and undergoing 
continuous growth, they require more glucose supply. Moreover, cancer cells are 
more likely to undergo anaerobic glycolysis or fermentation without citric acid 
cycle and oxidative phosphorylation. That means the energy production in form of 
ATP from glucose is less effective in cancer cells compared with normal cells. As 
a result, cancer cells should be affected more if the expression of Gluts were 
inhibited by the antisense method. 
In this project, human breast cancer cell line MCF-7 was used to study the 
antiproliferative effect of inhibition of Glut-1 and Glut-5 over-expression by 
antisense of Glut. 
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Glut-1 is the major transporter of glucose in almost all tissues. Most tumor 
tissues overexpress this type of Glut. So if its expression is inhibited by antisense 
oligodeoxynucleotide (ODN), the antitumor effect should be more potent than 
Glut-5, although the physiological role of Glut-5 on tissues other than the small 
intestine is not yet known. 
Glut-5 is more tissue-specific than Glut-1. Only a few human tissues, such 
as, small intestine and testis express this glucose transporter in a detectable 
amount. The predicted antitumor effect of antisense O D N against Glut-5 should 
be less potent than that of Glut-1, since Glut-5 is mostly a fructose transporter. But 
the specificity of antisense Glut-5 should be larger than that of Glut-1 due to the 
special tissue distribution pattem of Glut-5. 
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1.3) Antisense strategies 
Antisense strategies involve the applications of antisense 
oligodeoxynucleotides, ribozymes and full-length antisense R N A in treating 
diseases including cancers. Antisense oligodeoxynucleotides are short D N A 
sequences, usually 15 to 21 bases long, which are complementary to the partial 
sequences of target m R N A . The base-specific pairing of antisense molecule to the 
target m R N A can prevent translation or gene expression. Antisense 
oligodeoxynucleotides (ODN) and their modifications can inhibit gene expression 
specifically in many cell culture systems (Stein et al, 1993). 
Antisense ribozymes 
Ribozymes are small R N A molecules which can cleave other R N A 
molecules and specific m R N A sequences. These apparently catalytic R N A 
molecules occur naturally and can be divided into three major classes. The first 
class is group I introns, which occur in the gene for nuclear 26S rRNA in 
Tetrahymena thermophila. The second class is group II introns, which occur in 
organellar genes of lower eukaryotes and plants. The final class is small plant 
pathogenic R N A molecules, occurring in satellite RNAs and virusoids, which play 
some role in viral replication (Gibson, 1997). 
The ability of ribozymes to cleave R N A sequences has resulted in the design 
of hammerhead ribozymes. This hammerhead structure consists of three base-
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paired stems with a consensus sequence, resembling a hammer. Cleavage of the 
phosphodiester bond occurs at a unique site and generates 2',3'-cyclic phosphate 
and 5'-hydroxyl termini. The structure in three dimensions, however, resembles a 
wishbone. The three stems diverge at an acute angle and the third points in the 
opposite direction. The core is held together by base-pairing interactions. There is 
intense activity at this time in the unearthing of R N A structures and the various 
conformations and chemical links making up their organization. 
Ribozymes are different from antisense molecules and cleave their target 
m R N A following binding. Antisense molecule itself cannot cleave m R N A , such 
that RNase H or other enzymatic proteins must be involved in its mechanism. 
Full-length antisense RNA 
Full-length antisense R N A requires expression vectors to function in the 
transfected cells (Bielinska et. al., 1996). The cells therefore must be first 
transfected by electroporation or liposomal methods. After the transfection 
processs, the expression vector should express the cloned antisense sequence to 
antisense R N A molecule. The antisense R N A molecules expressed in the cell are 
then bind to the complementary m R N A and inhibit the gene expression process, at 
the level of translation or R N A processing. 
In our previous studies, we have investigated the effect of full-length 
antisense R N A targeted against human glucose transporter type-1 on cancer cell 
line HL-60, which is a human cancer cell line of leukemia. The results show that 
the antisense molecule can inhibit the expression of glucose transporter type-1 
which can be demonstrated by Northern blot analysis (Figure 1.7). Antisense 
Glut-1 R N A can also inhibit the proliferation of HL-60 by 50 — 60 % in vitro 
(Chan et. al, 1999). 
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Figure 1.7: Northern analysis o f full-length antisense RNA against Glut-1. For the top panel, 
the lanes from left to right are: negative control, full-length sense R N A control, full-length 
antisense R N A against Glut-1 and expression vector control. The bottom panel showed the 
normalization of total RNA 18S and 28S (Adaptedfrom Chan et. al., 1999). 
Antisense oligodeoxynucleotide 
In this project, only antisense oligodeoxynucleotide method was studied. 
This is because the method is more likely to be converted to human therapeutic 
application. Besides, ribozyme method makes use of R N A molecules, which are 
more ready to be cleaved by the nucleases present in cytoplasm and serum added 
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medium, therefore, it is not as stable as antisense oligodeoxynucleotide. 
i) The mechanism of antisense technique. 
Figure 1.8 shows the possible mechanism of antisense action. When 
antisense molecules are introduced into cells by lipofectin transfection. The 
antisense molecules can be located in the cytoplasm and binds to the taget m R N A 
there. Such complementary binding produces D N A / m R N A complex that may be 
cleaved by RNaseH in the cytoplasm. The translation then can be prevented. 
This is also possible that the transfected antisense molecules may enter the 
nucleus by DNA-binding proteins or diffuse through nuclear pores. At the 
nucleus, the antisense molecules may form a triplex structure with a double-
stranded genomic D N A sequence and the third strand possibly binds in the major 
groove of the duplex. 
Other possible mechanisms can be the prevention of R N A processing, that 
is R N A splicing, 5'-capping and 3'-polyadenylation. Moreover, the prevention of 
R N A translocation may also be involved in antisense action. 
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^hort oligodeoxynucleotide with sequence complementary to part of the target mRNA 
Introduce into cells 
t 
At the cytoplasm] ]Entry into the nucleus 
Binds to mRNA Form a triplex structure with a double-stranded DNA and the third 
strand binds in the major groove of the duplex 
RNaseH 
Prevent translation Prevent transcription 
Figure 1.8: Possible mechanisms of antisense action (Adaptedfrom Gibson,1997). 
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ii) Modification of oligodeoxyn ucleotides, 
Although there are accumulating experimental evidences showing that 
antisense technique can inhibit gene expression specifically in cell culture 
systems; there are two major problems in this technology. The first one is the poor 
spontaneous entry of oligodeoxynucleotides into the cells. The cellular uptake and 
transfection of antisense molecules into cells will be discussed in the part of 
cellular uptake of oligonucleotide. The second problem is the stability of 
oligonucleotide against nucleases which exist in cytoplasm as well as in serum. 
These exonucleases and endonucleases can cleave oligonucleotide at 
phosphodiester linkage and remove the functional antisense molecules. 
Oligonucleotides with phosphodiester backbone are sensitive to both 
exonuceases and endonucleases. Their half-lives are short in serum-added 
medium, in cells and in organisms. In order to increase the resistance of antisense 
molecules against nucleases, modified oligodeoxynucleotides are used. There are 
many possible chemical modifications on the short D N A molecule, such as, 
phosphorothioate and methylphosphonate modifications (Figure 1.9). Moreover, 
there is peptide nucleic acid (PNA) oligomers that the nitrogenous bases 






Figure 1.9: Modifications of oligodeoxynucleotides. For unmodified ODN , the X is oxygen ion 
(0') with one negative charge. For phosphorothioate modofication, the X is sulphur ion (S") with 
one negative charge. For methylphosphonate modification, the X is methyl group (-CH3) and the 
ODN is neutral. The Y position can be A, G, C or T. The Z position is hydrogen (H) atom. 
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Figure 1.10: Chemical structures of DNA ⑴ and PNA (2) showing the s . . . l an ty between 
the structores. B is the nucleobase. R^ is I ys . e amMe and R^ is p ‘ carboxamMo acndine 
(Adapted from Nielsen et. al., 1993) 
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One example is shown in Figure 1.11 that the phosphorothioate modified 
oligodeoxynucleotide is more stable in normal human serum than the unmodified 
oligodeoxynucleotide (Akhtar et. al. 1991). 
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F i g u r e 1.11: Degradation of 5 ， e n d [-'"?] labeled oligodeoxynucleotides (14 mer) in normal 
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3 is 20 minutes, lane 4 is 30 minutes, lane 5 is 60 minutes and lane 6 is the control fAdaptedfrom 
Akhtar ei. al.. 1991). 
3 9 
1.4) Cellular uptake of oligonucleotides 
Since the spontaneous uptake of oligodeoxynucleotide (ODN) into the cell is 
very low, methods were developed to transfect cells with the short D N A 
molecules. (For antisense application, the length of O D N is varied from 15 bases 
to 30 bases.) These methods are: microinjection, electroporation and cationic 
lipids transfection. For microinjection, this is impossible to inject every cancer 
cells in vitro and in vivo. For electroporation, although very high transfection 
efficiency can be achieved, such as near 100 % for viable cells (Bergan et. al, 
1993), the non-specific cytotoxic effect is also very serious. Besides, the 
application of electroporation in vivo is very difficult. 
Cationic lipids 
Cationic lipids were first used in cultured cells by Feigner et. aL (1987) in 
the introduction of a transient expression vector into a number of mammalian cell 
types. Malone et. aL (1989) later developed a method for transfection with 
mRNA. Since then cationic lipids have been routinely used for the delivery of 
antisense O D N (Bennett, 1992： Capaccioli et. al., 1992： Cumin et. al., 1993), and 
for the transfection of ribozymes into cells (Sioud, 1994; Leopold et. aL, 1995; 
Kariko et. al, 1994; Malone, 1995) A range of cell types, mammalian and 
otherwise, have been transfected using cationic lipids (Malone et. al, 1989; 
Karger and Komro, 1990). Moreover, in vivo transfection has also been 
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successfully carried out (French et. al, 1994; Feigner et. al, 1995). 
There are a number of cationic lipids now commercially available. Table 1.3 
shows some of them. 
Hydrophobic binding domain Monoamine Polyamine 
Oleic acid Lipofectin (DOTMA), 
DOTAP 
Lipofectamine (DOSPA) 
Short chain andy^ or saturated 
lipids 
DMRIE-C D O G S 
Cholesterol DC-Chol 
Table 1.3: The commercially available cationic lipids (Adaptedfrom Gibson, 1997). 
Advantages of using cationic lipids in transfection of oligodeoxynucleotides 
It has been reported that cationic lipids can improve antisense 
oligonucleotide uptake and prevent degradation in cultured cells and in human 
serum. For example, at the O D N levels normally used in antisense-mediated gene 
regulation experiments, a cationic lipid, DOTAP, enhances the rate of O D N 
uptake more than 25 fold (Capoccioli et. al., 1993). Moreover, O D N degradation 
by nucleases is markedly prevented by DOTAP both in cultured cells and in 
human serum (Capoccioli et. al, 1993). Other cationic lipids, namely D O T M A 
and D O G S have similar properties (Capoccioli et. al, 1993). 
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Key of the project: 
Phosphorothioate modified antisense oligodeoxynucleotide was used in this 
project, because it can enhance the stability of antisense oligodeoxynucleotide 
against nucleases. 
Cationic lipid, Lipofectin (DOTMA) was studied in this project to investigate 
its effect on cellular uptake of O D N by flow cytometry and confocal microscopy. 
The effect of Lipofectin on cellular uptake of O D N was also compared with that 
of hyperthermia. 
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1.5) Hyperthermia and combined treatments 
Hyperthermia 
Hyperthermia (HT) is a treatment involves applying heat with temperatures 
higher than the normal body temperature, such as 43°C to treat the tumor-bearing 
patients. H T can increase the cellular uptake of certain antitumor drugs, such as， 
doxorubicin (DOX) in vitro. It is reported that hyperthermia at 43°C increased the 
cellular uptake of doxorubicin in the nuclei of two esophageal squamous cell 
carcinoma cell lines, TE-2 and TE-6 (Kawai et. al, 1997). For the effect ofHT in 
vivo, it is reported that in rodent model Sprague-Dawley rats, hyperthermia at 
43°C exhibited increased doxorubicin concentrations for all intra-abdominal 
tissues (Jacquet et. al, 1998). In human clinical trial, it is reported that 
hyperthermia used alone caused complete clinical regression in 10-15% of 
tumors, however, the duration of response was very short (Vernon C., 1992). 
Combined treatment 
Combined treatment is the combination of two or more individual treatments 
in order to reduce the dose of individual treatment, such that the toxic side effect 
of each individual treatment can be minimized. The combined effects of this 
treatment can be synergistic, additive or substrative. 
In this thesis, we have examined the effect of combined treatment of 
hyperthermia plus the antisense O D N on MCF-7 cells. 
幻 
Key of the project: 
Since hyperthermia (HT) can enhance the cellular uptake of certain antitumor 
drugs, it is of interest to examine whether HT can also enhance the uptake of short 
antisense ODN. So in the present project, the effect of hyperthermia at 43°C on 
the uptake of Fluorescein (FITC) - labeled phosphorothioated 
oligodeoxynucleotides (FITC-ODN) in various human tumor cell lines were 
studied. 
If HT can enhance the cellular uptake of FITC-ODN, then the effect of 
combined treatment between hyperthermia and antisense against Glut will be 
investigated. Our results may provide an alternative option for combined 
treatment using hyperthermia and antisense strategies. 
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Chapter 2: 
Materials and methods 
2.1) Materials: 
2.1a) Cell lines and culture media. 
MCF-7, MDA-MB-231, Caco-2 and HepG-2 were purchased from the 
American Type Culture Collection (Rockville, MD). The cells were cultured in 
RPMI-1640 with 10 % heat inactivated fetal bovine serum (Gibco BRL, USA) 
and were maintained at 37 °C，5 % carbon dioxide with triple media changes 
weekly. Trypsin-EDTA was also purchased from Gibco BRL(USA). 
2.1b) Oligonucleotides synthesis: 
Antisense phosphorothioated oligodeoxynucleotide (ODN) molecules 
against Glut-1 and 5, both 15 bases length, were designed in our laboratory and 
synthesized by Gibco BRL (Hong Kong Branch). The coupling efficiency stated 
was 98 % and was purified by cartridge. The sequence of antisense Glut-1 was 
complementary to human glucose transporter type-1 cDNA sequence around the 
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start codon region started at 169. The 5' to 3’ sequence was: 5'- C C A T G G C A G 
C G C T G C -3'. The sequence of sense control for Glut-1 was the same as the start 
codon region of human glucose transporter type-1 cDNA. The 5’ to 3，sequence 
was: 5'- G C A G C G C T G C C A T G G -3'. The O D N was phophorothioated at each 
base. 
For antisense Glut-5 the sequence was complementary to human glucose 
transporter type-5 cDNA sequence around the start codon region started at 70. 
The 5’ to 3’ sequence was: 5,- TTG CTC CAT GCT TGC -3,. The sequence of 
sense Glut-5 was the same as the start codon region of human glucose transporter 
type-5 cDNA sequence. The 5’ to 3’ sequence was: 5'- G C A A G C ATG G A G 
C A A -3'. The O D N was phophorothioated at each base. 
Fluorescein (FITC) - labeled phosphorothioated oligodeoxynucleotide 
(ODN), 15 bases length, was also synthesized by Gibco BRL. Fluorescein was 
covalently bound to ODNs at 5’ end. The coupling efficiency stated was 98 % and 
was purified by cartridge. The sequence of 15 bases FITC-labeled O D N was 
antisense Glut-5. The 5' to 3’ sequence was: Fluoro-TTG CTC CAT GCT TGC. 
The labeled O D N was also phophorothioated at each base. 
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2.1c) Chemicals: 
D O T M A / DOPE solution (Lipofectin) was purchased from Gibco BRL 
(USA). 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (thiazolyl 
blue) (MTT), and propidium iodide (PI) were purchased from Sigma. Acridine 
Orange (AO) was purchased from Molecular Probe. 
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2.2) Methods: 
2.2a) Oligonucleotide design, 
The c D N A sequences of human glucose transporter type 1 to 7 are shown in 
Figure 2.1 to 2.7. The oligonucleotide design is based on the start codon region of 
Glut-1 and Glut-5, since MCF-7 overexpressed both of the two Gluts without the 
expression of Glut-3. The antisense molecules are complementary to the target 
sequences of m R N A . For example, if the target sequence is 5'- A A A G G G TTT 
CCC - 3', then the antisense molecule should be 5'- G G G A A A C C C TTT - 3'. 
The antisense molecules used in this project were 15 bases chain. 
The antisense molecules were phosphorothioated at each bases at the site of 
phosphorus atom of the phosphodieaster linkage. This is to increase the nuclease 
stability, and to enhance the antisense effect. 
k 
The selected sequences of antisense Glut-1 and Glut-5 were checked against 
GeneBank database through internet for the specificity, the wetsite is: 
http://www.ncbi.nlm.nih.gov. using the program "Blast ” 
The 5’ to 3' sequence for antisense Glut-1 started at site 169 of human 
Glut-1 cDNA sequence was: 5'- C C A T G G C A G C G C T G C -3,. The 5，to 3， 
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sequence for sense Glut-1 was: 5'- G C A G C G C T G C C A T G G -3'. The O D N 
was phophorothioated at each base. This sequence of antisense Glut-1 has been 
using in our laboratory and we have demonstrated that it can inhibit the 
expression of Glut-1 m R N A in human tumor cells lines (Chan et. al., 1999). 
The 5’ to 3’ sequence for antisense Glut-5 started at site 70 ofhuman Glut-
5 cDNA sequence was: 5'- TTG CTC CAT G C T T G C -3'. The 5，to 3' sequence 
for sense Glut-5 was: 5'- G C A A G C ATG G A G C A A -3'. The O D N was 
phophorothioated at each base. 
The sequence of 15 bases FITC-labeled O D N was antisense against human 
glucose transporter type-5 cDNA sequence around the start codon region. The 5’ 
to 3，sequence was: Fluoro-TTG CTC CAT GCT TGC. The labeled O D N was 
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Figure 2.1:The cDNA sequence ofhuman glucose transporter type-
sequence for antisense treatment. 
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Figure 2.2: The cDNA sequence ofhuman glucose transporter type-
5 1 
Origin: cDNA sequence ofhuman glucose transporter type-3 
Length: 
Content of A: 
Content of C: 
Content of G: 
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3541 ACTAAAAATG CAAAAATTAG CCGGGCGTGG TGGCGGGCGC CTGTAATCCC AGCTACTTGG 
3601 GAAGCTGAGG CGGGAGAATC ATGTGAACCC GGGACGCAGG GGTTGCAGTG AGCGGAGATC 
3661 GCATCATTGC ACTCTAGCCT GGGCCACAGG GCGAGACTCC GTCTCAAAAA AAAAAAAATG 
3 721 CACATAGCTA TCGAGTGTGC TTTAGCTTGA AAAGGTGACC TTGCAACTTC ATGTCAACTT 
3781 TCTGGCTCCT CAAACAGTAG GTTGGCAGTA AGGCAGGGTC CCATTTCTCA CTGAGAAGAT 
3841 TGTGAATATT TCCATATGGA TTTTCTATTG TTACTCTGGT TCTTTGTTTT AAAATAAAAA 
3901 TTCTGAATGT ACACG 3 ' 




Content of A: 
Content of C: 
Content of G: 
Content ofT: 
Coding region 




























































































































































































































































Figure 2.4: The cDNA sequence ofhuman glucose transporter type-4. 
5 4 
Origin: cDNA sequence ofhuman glucose transporter type-5 
Length: 2218bp 
Content ofA: 457 
Content ofC: 607 
Content ofG: 593 
Content ofT: 561 
































































































































































































































































Figure 2.5: The cDNA sequence ofhuman glucose transporter type-5. The box indicates the target 
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Content of C: 
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Content ofT: 



































































































































































































































































Figure 2 .7: The cDNA sequence ofhuman glucose transporter type-7. 
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2.2b) Oligonucleotide treatment: 
One ml PBS was added to lyophilized antisense molecules or FITC-ODNs. 
The O D N solution was then measured against absorbance at 260 nm to determine 
the concentration. The solution was then filtered through 0.22 ^ im Cameo 25AS 
acetate filters. 
For flow cytometric studies, cells were seeded at 24-well plate for 100,000 
cells per well. For confocal microscopic investigation, 250,000 cells per well were 
seeded on a round cover glass in the 6-well plate. For antiproliferative studies, 
cells were seeded at 96-well plate for indicated cell densities. After 24 hours 
incubation in 37°C and 5 % CO2 level, it is for the cells to adhere onto the bottom 
of the wells. The cells were then washed twice with RPMI 1640 without serum 
and antibiotic. 
For Lipofectin transfection, semm-free RPMI-1640 without antibiotic was 
used in all cases. Lipofectin (DOTMA) was added to RPMI 1640 and incubated at 
room temperature for 45 minutes. The sterilized O D N solution was added to 
RPMI 1640 and mixed with D O T M A in RPMI 1640 to obtain mixtures with 
desired concentrations and O D N to Lipofectin w/w ratios. The mixed solution was 
further incubated at room temperature for 15 minutes to allow O D N / Lipofectin 
complexes formation and it was then added to treat cells. 
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For hyperthermia treatment, only O D N in RPMI 1640 without serum and 
antibiotic was introduced. The treated cells were placed in incubators and 
incubated at 2>TC or 43°C with 5 % CO2 for indicated time periods. 
2.2c) Flow cytometry: 
After the incubation with Lipofectin or treated at 43°C, the treated cells were 
washed twice with 1 ml ice cold PBS. The adhered cells were trypsinised and 
centrifuged at 85 g for 3 minutes. The supematant was removed and RPMI 1640 
without phenol red was added. Cells were resuspended and acquired on the 
system of FACsort flow cytometer (Becton Dickinson). The acquisition of cells 
were analysed by Lysys II program (Becton Dickinson). An excitation filter with 
488 nm wavelength (Argon laser) was selected. The population of cells were 
determined by forward scatter (FSC) light and side scatter (SSC) light. FSC and 
SSC determine the size and the granularity of a cell respectively. The signal of 
FITC was collected at channel FL-1 (green fluorescence) and the signal ofPI was 
collected at channel FL-3 (red fluorescence). For the flow cytometric analysis, the 
fluorescence properties of 10,000 cells were collected. 
2.2d) Confocal microscopy: 
After hyperthermia or Lipofectin transfection, the cells were washed twice 
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with 1 ml ice cold PBS. Half ml PBS was used during the experiment. Images of 
cells were acquired on Multiprobe 2001 from Molecular Dynamics that fitted with 
an argon laser 6 m W at excitation and Nikon diaphot inverted microscope. An 
excitation filter with 488 nm wavelength and a long-pass emission filter of 510 
nm were used. Cells were scanned by using a 60X fNikon planApo) or 100X 
(Nikon, Fluor) oil objectives with low-fluorescence immersion oil (Stephens 
Scientifies, USA). The voltage of Photomultiplier Tube (PMT) was set at 
optimum. Images were processed by an image analysis software (Imagespace 
3.1). 
2.2e) MTT assay for cytotoxicity or cell proliferation: 
Cells were seeded at indicated cell densities on 96-well plate. After 
antisense treatment or hyperthermia for indicated time periods, medium was 
removed and 50 ^il of 2 mg/ml M T T in PBS was added to each well. The 96-well 
plate was then incubated for 2 hours at 37°C incubator. After the incubation, 100 
l_d 0.04N HC1 acidified isopropanol was added to dissolve the dark blue colored 
crystal. The plate was further incubated at 43。C for 15 minutes. Absorbance ofthe 
wells at 540 nm was determined by microplate reader (Bio-rad, model 3550). 
Fifty |ul M T T and 100 ^il acidified isopropanol was used as blank. 
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Chapter 3 
Cellular uptake of oligonucleotide spontaneously and 
Lipofectin-aided 
3.1) Introduction: 
Antisense oligodeoxynucleotides (ODN) and their modifications have well 
been studied. It has been shown that antisense O D N can inhibit gene expression 
specifically in many cell culture systems (Stein et al., 1993). However, two major 
problems affecting its efficiency and development into cancer therapy are the poor 
cellular uptake and poor stability towards nuclease cleavage. 
Unmodified phosphodiester oligodeoxynucleotides are cleaved by various 
nucleases in medium and cytoplasm rapidly at the phosphodiester linkage. As a 
result, relatively larger amount of ODNs, such as 5 - 500 ^iM, are required to 
achieve detectable inhibition of gene expression (Krol et. al, 1988). 
Methylphosphonates and phosphorothioates are the most commonly used 
modifications and the modified ODNs have been shown to be more stable and so 
should be more effective than unmodified ones in cell culture assays (Akhtar et. 
al.，1991). 
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Synthetic cationic lipids were first used by Feigner et al (1987) in 
transfection of plamid D N A s into cultured cells. Since then, many studies focused 
on the use of cationic lipids, such as, DOTAP, D O T M A and D O G S , in an attempt 
to enhance the cellular uptake of antisense ODNs. It is reported that cationic lipids 
can enhance the cellular uptake as well as the activities of phosphorothioated 
antisense oligodeoxynucleotides in a number of cell culture systems, such as 
H U V E C (Bennett et. al, 1992), 
In our experiment, the cationic lipid used was Lipofectin reagent purchased 
from Gibco BRL. Lipofectin reagent is a 1:1 (w/w) liposome formulation of the 
cationic lipid N-[ 1 -(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride 
(DOTMA), and dioleyl phosphotidylenthanolamine (DOPE) dissolving in 
membrane filtered water. 
In this chapter, we examined the effect of Lipofectin-aided transfection on 
cellular uptake of FITC-labeled ODNs in human breast cancer cells with estrogen 
receptors (MCF-7 cells). The effect was also compared with spontaneous cellular 
uptake of O D N . The O D N used in this experiment was antisense Glut-5 ( See 
Materials and Methods). 
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3.2) Flow cytometric studies: 
i) Lipofectin transfection can enhance the O D N uptake in MCF-7 cells: 
Figure 3.1 shows the histogram of the uptake of FITC-ODN in MCF-7 cells 
measured by flow cytometry. "FLl-Height per unit" was plotted against "Events" 
using the program W I N M D I 2.6. "FLl-Height" is equal to the green fluorescent 
intensities in tested cells per unit. "Events" are related to the number of cells 
containing a particular amount of green fluorescent intensities. 
The mean fluorescent values are relative values depend on the setting of 
P M T amplifications. It is derived from the total fluorescent intensity divided by 
total cell amount. As a result, the values are used for comparison between samples 
within the test. They are not absolute numbers. 
Under the present experimental condition, the uptake of O D N into the cells 
was 23 fold higher on average in Lipofectin-transfected group than the 
spontaneous uptake control group (Figure 3.1). 
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Figure 3.1: The effect of Lipofectin on cellular uptake of FITC-ODN. For Lipofectin-aided 
oligodeoxynucleotide uptake, the MCF-7 cells were seeded for 100,000 cells per well in a 24-well 
plate and incubated for 24 hours at 37°C. The cells were washed twice with semm free RPMI-
1640. For negative control, only serum-free R P M I was introduced and was incubated at 37。C and 
5 % CO2 for 24 hours. For 8 ^iM control, the cells were incubated with 8 ^ M FITC-ODN for 24 
hours without Lipofectin reagent. For Lipofectin treatment (8 ^M-1:1), cells were incubated with 8 
) iM FITC-ODN and Lipofectin in 1:1 w/w ratio for 15 hours followed by medium exchange with 
medium containing normal serum and they were further incubated in 37。C for 9 hours. The 
samples were measured by flow cytometry. The curves from left to right are negative control, 8 
|_iM control and Lipofectin treatment (8 ^M-1:1). The signals o f fluorescence o f FITC (green 
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ii) The effect of O D N to Lipofectin (w/w) ratios on the uptake of O D N in MCF-7 
cells: 
In this investigation, 0.5 ^ iM FITC-ODN was used in all samples except the 
negative control where no FITC-ODN was added. The transfection time was 15 
hours at 37°C. The transfection protocol was described in Materials and Methods. 
The MCF-7 cells (100,000 cells per well) were seeded in a 24-well plate for 24 
hours at 37。C. The molecular weight for the 15 bases FITC-ODN was 4,748 ^ ig / 
|jmol. For 0.5 ^ iM O D N in 0.5 ml serum free RPMI 1640, about 1.187 jug ofODN 
was added. As a result, in order to prepare a mixture with 1:10 w/w ratio of O D N 
to Lipofectin, 11.87 ^ ig of Lipofectin was added. Mixtures with other ratios were 
also prepared. 
The mean fluorescent values (^ er units), for the negative control, 0.5 ^ iM 
O D N without Lipofectin, w/w ratios of O D N to Lipofectin 1:1.25, 1:2.5, 1:5 and 
1:10 were 3.2, 32.8, 42.0, 62.3，321.5, 1112.3 respectively. When comparing the 
data of O D N to Lipofection ratio 1:10 with that of 0.5 ^ iM without Lipofectin 
(spontaneous uptake), there were about 34-fold increase in FITC-ODN uptake on 
average. Moreover, increase the ratio (w/w) of O D N to Lipofectin can enhance 
the uptake ofFITC-ODN (Figure 3.2). 
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F i g u r e 3.2: The effect of the ratio of O D N to Lipofectin (w/w) on FITC-ODN uptake of 
MCF-7 cells. MCF-7 cells were seeded for 100,000 cells per well at 24-well plate and were 
incubated at 37。C for 24 hours. The cells were washed twice with serum free RPMI-1640. 0.5 |iM 
FITC-ODN was used in all samples except the negative control where no FITC-ODN was added. 
The transfection time was 15 hours at 2>TC. The transfection protocol was mentioned in Materials 
and Methods. The samples were measured by flow cytometry. The curves from left to right are 
negative control, 0.5 ^iM FITC-ODN without Lipofectin, O D N to Lipofectin w/w ratio 1:1.25, 
1:2.5, 1:5 and 1:10. The signals of fluorescence of FITC (green fluorescence) were collected at 
channel FL-1 of the flow cytometer. 
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Samples Mean Fluorescence Value / units 
Control 3.2 
No Lipofectin 32.8 
1 : 1.25 42.0 
1 : 2.5 62.3 
1 : 5 321.5 
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iii) The effect of O D N concentrations on its uptake in MCF-7 cells: 
In this Lipofectin-aided O D N uptake study, the amount ofLipofectin used in 
all samples except negative control was under the ratio 1:1 w/w O D N to 
Lipofectin. The transfection time was all 15 hours at 37°C. For the negative 
control, only serum free medium was added. 
The FITC-ODN concentrations varying from 0.5 ^ iM to 8 |aM with 2-fold 
increases were used. The mean fluorescent values of negative control, 0.5 ^ M, 1 
^iM, 2 ^ iM, 4 ^ iM and 8 ^ iM samples were 3.4, 44.0, 68.5, 125.9, 542.0, 1327.9 
units respectively. The results indicate that the Lipofectin-aided cellular O D N 
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F L l - H e i g h t 
Samples Mean Fluorescence Value / units 
Control 3.4 
0.5 ^iM 44.0 
1 ^iM 68.5 
2 ^iM 125.9 
4^iM 542.0 
8 ^iM 1327.9 
F i g u r e 3.3: The effect of O D N concentrations on FITC-ODN uptake of MCF-7 cells. MCF-
7 cells were seeded for 100,000 cells per well at 24-well plate and were incubated at 37。C for 24 
hours. The cells were washed twice with serum free RPMI-1640. The amount of Lipofectin used 
in all samples except negative control was under the ratio 1:1 w/w O D N to Lipofectin. The 
transfection time was all 15 hours at 37°C. For the negative control, only serum free medium was 
added. The FITC-ODN concentrations varied from 0.5 fiM to 8 ^iM with 2-fold enlargement. The 
samples were measured by flow cytometry. The curves from left to right are negative control, 0.5 
^iM FITC-ODN, 1 ^ M , 2 ^iM, 4 ^ M and 8 ^iM. The signals of fluorescence of FITC (green 
fluorescence) were collected at channel FL-1 of the flow cytometer. 
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iv) The effect of transfection time on Lipofectin-aided O D N uptake in MCF-7 
cells: 
In this experiment, the concentration of FITC-ODN used was 4 ^iM except 
the negative control which contained only serum free RPMI medium. The O D N to 
Lipofectin w/w ratio was all 1:1 and the transfection time studied were 5 hours, 15 
hours and 24 hours at 2>TC. 
The mean fluorescent values for negative control, 5 hours transfection time, 
15 hours, and 24 hours were 3.1, 250, 542, and 546 units respectively. These 
results indicate that Lipofectin-aided O D N uptake was transfection time 
dependent and can be saturated (Figure 3.4). 
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F i g u r e 3.4: The effect o f transfection time on FITC-ODN uptake in MCF-7 cells. MCF-7 
cells were seeded for 100,000 cells per well at 24-well plate and were incubated at 37°C for 24 
hours. The cells were washed twice with serum free RPMI-1640. In this experiment, the 
concentration o f F ITC-ODN used was 4 ^ M except the negative control, which contained only 
serum free R P M I medium. The w/w oligonucleotide to Lipofectin ratio was all 1:1 and the 
transfection time varied from 5 hours, 15 hours to 24 hours at 37°C. The samples were measured 
by flow cytometry. The curves from left to right are negative control, 5 hours transfection, 15 
hours transfection and 24 hours transfection. The signals of fluorescence o f FITC (green 
fluorescence) were collected at channel FL-1 of the flow cytometer. 
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From left to right: 
1) control 
2) 5 hours 
3) 15 hours 
4) 24 hours 
Samples Mean Fluorescence Value / units 
Control 3.1 
5 hours 250.0 
15 hours 542.0 








3.3) Confocal microscopic studies: 
Examination of cellular distribution of FITC-ODN in MCF-7 cells by confocal 
microscope: 
This study investigated the intracellular distribution of FITC-ODN after 
uptaken by MCF-7 cells using confocal microscopy. The detailed procedures were 
described in Materials and Methods. The excitation wavelength used was 488 nm 
and emission wavelength was 510 nm. MCF-7 cells were scanned vertically by 
0.5 ^ m sections from bottom to top of the cells (Figure 3.5a to 3.5d). The typical 
pictures of the central optical section were shown in Figure 3.6. 
The cells MCF-7 were seeded for 250,000 cells per well on a round cover 
glass in the 6-well plate. They were then incubated at 37°C and 5 % CO2 for 24 
hours. The cells were washed twice with serum-free RPMI-1640. For negative 
control, only serum-free RPMI-1640 medium was added and the cells were 
incubated at 37°C for 15 hours. They were then washed twice with ice cold PBS. 
The picture shows that no fluorescent signal could be detected by the confocal 
microscope, but signals appeared after staining with Acridine Orange (AO) at a 
final concentration of 1 ^ M (Figure 3.6a). 
For spontaneous O D N uptake, 8 ^ iM FITC-ODN was added in serum free 
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RPMI-1640 and the cells were incubated at 37°C for 15 hours. They were then 
washed twice with ice cold PBS. From the image, it was found that FITC-ODN 
had been uptaken mainly into the cytoplasm of the cells spontaneously and they 
were concentrated at some cytosolic regions (Figure 3.6b). 
For Lipofectin-aided transfection, 4 jaM FITC-ODN was used with O D N to 
Lipofectin w/w ratio 1:1 in serum-free RPMI-1640. The transfection time was 15 
hours at 37°C. By confocal imaging, it was observed that the FITC-ODN was 
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Figure 3.5: The intracellular disMbution of FITC-ODN in MCF-7 cells by confocal 
microscope. The excitation wavelength was 488 nm and emission wavelength accepted was 510 
mn. MCF-7 cells were scanned verticaUy by 0.5 pm sections from bottom to top of the cell 
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particles. The cells were seeded for 250,000 cells per well on a round cover glass in the 6-weIl 
plate. They were then incubated at 37。C and 5 % CO2 for 24 hours. The cells were washed twice 
with serum-free RPMI-1640. For spontaneous O D N uptake, 8 ^iM F ITC-ODN was added in serum 
free RPMI-1640 and the cells were incubated at 37°C for 15 hours. They were then washed twice 
with ice cold PBS and measured by confocal microscope (Figure 3.5a). The plate was then stained 
with Acridine Orange (AO ) at the final concentration o f 1 ^iM (Figure 3.5b). For Lipofectin 
transfection, 4 ^iM FITC-ODN was used with O D N to Lipofectin w/w ratio 1:1 in serum-free 
RPMI-1640. The transfection time was 15 hours at 37°C (Figure 3.5c). The plate was then stained 





• ^ • • ^ • • P I ^ I H 
^ H ^ ^ ^ n 
| ^^^^^ | | ^ te^^V | 
^ ^ ^ ^ ^ ^ ^ ^ ^ • 1 . H^niil^^H#J 
W^^^mMm 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^¾^^^^^^¾!^^^^^^^^^* ^^ ^^ ^^ ^^ ^MiHBBH^HBPIH|BBBBHBBBHHIBHBIHBHIPPmi^ -J|R(^ lHiShi^  




^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ p ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ .^ 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^H^^^^^^^^^^^^^^^^^^^^i 4. w^^^^^^^^^^^^^^^^^^^^^^^^m^^*D^pm^^^^^^^^^^^^^^^^^^ 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^H^^^^^^^^^^^^^^^^^^^^^^^^^H rj^, X： ^^^^^^^^^^^^^^^^^^^^^^^^m ^^Mi ^ . -M. ^ HH^^^^^^^^^^^^^^^^^^^H 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^1 ‘ ^ ^^^^^^^^^^^^^^^Hl ^ • SS^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^H 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H | H . ^ N'^  ^ B ^ ^ ^ ^ ^ ^ ^ ^ f t ^ 3 ^ 2 2 ^ ^ ^ ^ ^ ^ ^ ^ ^ l ' 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^Hf。瑰 ^^K _^^^vpi^i^^^^^^^^^mii i i i i^^pip^^^^^^^^^^^. 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^I^^^^^^^^l^^^^^^^^。 ‘ ^^ ^^ ||L^Bi^ £|u?V j' ^  '^ ^^^^^^^^^^^^^^^^B' m^^ ^ S^ - .. ^^ ^Hri^ ^^ ^| 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^v ^^ ^^ ^^ ^HLte T^L ‘‘ ^ fet'.^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^K' 1 ‘ -j^ H^^ ^^ ^^ B^' 
^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ;^i I ^^ ^^ ^^ ^^ ^^ ^^ HB^ |^||^ HK|B^ M^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ L^ w^ _jK^^^^^^^^^^^^ 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | " 。 ^ ^ ^ ^ ^ ^ ^ ^ / j j ^ ^ / j ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ / | | j | | ^ ^ ^ ^ ^ ^ ^ ^ ^ 
^ ^ ^ ^ ^ ^ ^ ^ H H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H V ^ ^ ^ ^ ^ ^ ^ ^ ^ b S m ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ' 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^1 y 广^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^| ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^P V ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^M 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^mi f i'^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ |^ 
^^^^^^^^^^^^^^^^^^M^ iHHpi^HiHiV i i i iWi i，,、�i ~^、I^^HHHHHIIH^^IHHHI^^IHHII^HHHI^^HIHI • • I I I I 
0 255 
Figure 3.6: The intracellular distribution of FITC-ODN on MCF-7 cells by confocal 
microscope. The excitatiwi wavelength was 488 nm and emission wavelength was 510 nm. MCF-
7 cells were scanned vertically by 0.5 pm from bottom to top of the cell particles. The pictures 
presented were chosen as believed to be the central reg im of the cell in vertical direction. The 
cells were seeded for 250,000 cells per well on a round cover glass in the 6-well plate. It was then 
incubated at 37°C and 5 % CO2 for 24 hours. The cells were washed twice with serum-free RPMI-
1640. For negative control, only serum free RPMI-1640 medium was added and the cells were 
incubated at 3 7 � C for 15 hours. They were then washed twice with ice cold PBS. The picture 
shows that no fluorescent signal can be detected by the confocal microscope (Left) and the cells 
were thai stained with Acridine Orange (AO) at a final concentration of 1 ^M (Right) (Pigure 
3.6a). For spontaneous uptake, 8 ^M FITC-ODN was added in serum free RPMI-1640 and the 
cells were incubated at 3TC for 15 hours. They were thai washed twice with ice cold PBS. From 
the image, it can be observed that FITC-ODN had been uptake mainly into the cytoplasm of the 
cells spontaneously and it was concentrated at some regions (Left). The cells was then stained with 
Acridine Orange (AO) at a final concentratirai of 1 ^M ^Right) (Figure 3.6b). For Lipofectin-aided 
transfection, 4 ^M FITC-ODN was used witii ODN to Lipofectin w/w ratio 1:1. The transfection 
time was 15 hours at 3TC. By confocal imaging, it can be observed that the FITC-ODN was 
mostly distributed at the cytoplasm of tiie cells after 15 hours transfection (Left). Moreover, the 
ODN was more widely distributed than that for the spontaneous uptake sample at the cytoplasm. It 
was then stained with Acridine Orange (AO) at a final concentration of 1 ^M ORight) (Figure 
3.6c). 
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3.4) Cytotoxic effect of Lipofectin alone on MCF-7 cells: 
M T T assay was carried out to study the cytotoxic effect of Lipofectin alone 
on MCF-7 cells. The cells at 20,000 cells per well were seeded in a 96-well plate 
and incubated at 37°C for 24 hours. The cells were then washed twice with semm 
free RPMI-1640. 
For Lipofectin toxicity assays, the transfection time was 24 hours which 
should be the maximum transfection time as stated on the product manual 
provided by the manufacturer. For the control group, serum-free RPMI-1640 was 
added. While for those test samples, Lipofectin were added to serum-free RPMI 
for indicated concentrations, as ^ ig Lipofectin per 200 ^ il serum-free RPMI. The 
percentage control survival rate for 0.3, 0.6，1.25, 2.5, 5 and 10 |ig / 200 ^ il were 
84 %, 83 % , 81 % , 72 % , 57 % and 34 % respectively (Figure 3.7). As a result, 
the higher the Lipofectin concentration, the larger is the cytotoxic effect. The 
possible reason is the molecular structure of D O T M A in Lipofectin is like a 
detergent (Figure 3.8). So in high concentration, Lipofectin reagent is toxic. 
Throughout this study, the concentration of Lipofectin used was usually not 
more than 5 i^g / 200 i^l which is not very toxic to MCF-7 cells. It has been 
reported that when Lipofectin is combined with oligodeoxynucleotides, its toxic 
8 0 
effect will be alleviated (Gibson, 1997). Furthermore, the sense control used in 
this study can exclude any cytotoxic effect from Lipofectin, because the sense 
control has all factors the same as antisense treatment except the O D N sequence. 
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F i g u r e 3 . 7 : The cytotoxic effect of Lipofectin on MCF-7 cells. The cells at 20,000 cells per 
well were seeded in a 96-well plate and incubated at 37。C for 24 hours. The cells were then 
washed twice with serum free R P M I 1640. The transfection time was 24 hours. For control group, 
only serum-free R P M I 1640 was added. Whi le for those test samples, Lipofectin were added to 
serum-free R P M I at the concentrations as indicated. The percentage survival was determined by 
V 
MTT assays. Results were means 土 SD o f 10 duplicates. 
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F i g u r e 3.8: The molecular structure of catiomc lipid N-[l-(2,3-dioleyloxy)propyl]-n,n,n-




Cellular uptake of oligodeoxynucleotide is one of the limitations on antisense 
research and therapeutic efficiency. There are several ways to enhance the uptake 
of O D N into the mammalian cells. Microinjection of FITC-labeled O D N into the 
cytoplasm of mammalian cells (Rat2) has shown to be highly localized in the 
nucleus (Fish et. aL, 1993). Electroporation has shown to achieve high 
intracellular concentrations of O D N in nearly 100 % of viable cells, the 
transfected O D N was found to be initially localize at the nucleus and remain there 
for at least 48 hours (Bargan et. al.，1993). Cationic lipids, such as, Lipofectin 
(DOTMA), were commonly used and studied in antisense field, it was reported 
that cationic lipids can improve oligonucleotide uptake and prevent degradation in 
cultured cells and in human serum (Capaccioli et. al., 1993). 
In this chapter, we have studied the effect of Lipofectin on cellular 
、oligodeoxynucleotide uptake using FITC-ODN on MCF-7 cells. It can be 
observed that Lipofectin can enhance the cellular uptake of FITC-ODN by flow 
cytometry comparing with spontaneous cellular uptake ofODN. The O D N uptake 
rate of Lipofectin-aided transfection is dependent on O D N to Lipofectin w/w 
ratios，oligonucleotide concentrations and transfection time. These three factors 
should be considered in optimizing the transfection effectiveness. Moreover, high 
concentrations ofLipofectin alone have cytotoxic effect on MCF-7 cells under the 
present experimental condition. However, it has been mentioned that Lipofectin 
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alone appears to be more cytotoxic than lipid-DNA complexes (Padilla, 
unpublished). 
By confocal microscope, it was shown that the internalized FITC-ODN was 
concentrated in the cytoplasm of MCF-7 cells after 15 hours transfection time 
period. So Lipofectin-aided transfection can introduce FITC-ODN into the cells 
and not just adhered on the cell surface. This result indicates that the date 
obtaining from flow cytometry are reliable as the FITC-ODN is internalized in the 
cytoplasm. 
Comparing the confocal data of the spontaneous cellular 
oligodeoxynucleotide uptake with the one aided with Lipofectin, it was found that 
Lipofectin-aided cellular O D N uptake was more widely distributed in the 
cytoplasm. While for the spontaneous O D N uptake, the O D N was concentrated at 
some regions in the cytoplasm which may possibly be the cellular vesicles or 
endosomes formed after endocytosis. 
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Chapter 4 
Hyperthermia can enhance oligonucleotide uptake 
4.1) Introduction: 
Hyperthermia (HT) is an anti-tumor treatment involving the application of 
heat at higher temperatures, such as 43 °C, on tumor cells. It was reported that H T 
can increase the cellular uptake of certain antitumor drugs, such as, doxorubicin 
(DOX) in vitro (Kawai et. aL, 1997) and in vivo (Jacquet et. aL, 1998). In human 
clinical trial, it was reported that hyperthermia used alone can cause complete 
clinical regression in 10-15% of tumors, however, the duration of response is very 
short. Combined treatment between hyperthermia and radiation can exert greater 
advantage in the local control of cancer growth (Vernon, 1992). 
V 
It is suggested that the combined treatment between hyperthermia and 
radiation or chemotherapy may have better effect in cancer therapy because the 
doctor can reduce the amount of chemical drugs or the dose of radiation if 
hyperthermia is also used. These combined treatment can reduce many serious 
side effects from chemotherapy and radiotherapy. Antisense technology is a new 
concept for cancer therapy. There are accumulating evidences showing the 
potential of this concept. In this chapter, we are going to study the possibility of 
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combined treatment between hyperthermia and antisense technology by studying 
the effect of hyperthermia on cellular uptake of antisense molecules. 
In this investigation, we used Fluorescein (FITC) labeled phosphorothioate 
oligodeoxynucleotides (ODN) as a substrate to study the effect of H T at 43°C on 
the cellular uptake of O D N . Four cell lines were studied: MCF-7, MDA-MB-231, 
Caco-2 and HepG-2. Flow cytometry and confocal microscopy were applied to 
study the uptake and distribution of ODNs respectively. 
4.2) Flow cytometric studies: 
i) Hyperthermia can enhance the oligonucleotide uptake on MCF-7 cells: 
Human breast cancer cell line MCF-7 was seeded in a 24-well plate for 
100,000 cells per well and incubated for 24 hours at 37°C. The cells were washed 
twice with serum free RPMI-1640. Eight ^ iM FITC-labeled O D N , which was 15 
‘\ 
bases long, in serum free RPMI 1640 was added. For control, only serum-free 
RPMI was introduced. For 37。C control, the cells were incubated at 37。C and 5 % 
CO2 with 8 ^ iM FITC-ODN for 24 hours. For the hyperthermia (HT) treatment, 
cells were incubated at 43。C and 5 % CO2 with 8 jaM FITC-ODN for 15 hours 
followed by 9 hours incubation in 37°C, such that totally 24 hours are used. It is 
for HT treated cells to recover after the hyperthermia treatment. 
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Cellular uptake of labeled phosphorothioated oligodeoxynucleotide was 
enhanced near 3 fold on average for H T group when compared with 37°C control 
group in which spontaneous O D N uptake has taken place (Figure 4.1). 
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F i g u r e 4 .1: The effect of hyperthermia on cellular uptake of FITC-ODN. Human breast 
cancer cell line MCF-7 was seeded in a 24-well plate for 100,000 cells per well and incubated for 
24 hours at 37°C. The cells were washed twice with serum free RPMI-1640. Eight }iM FITC-
labeled ODN , which was 15 bases long, in serum free RPMI-1640 was added. For control, only 
serum-free RPM I was introduced. For 37°C control, the cells were incubated at 37°C and 5 % CO2 
with 8 f iM FITC-ODN for 24 hours. For hyperthermia (HT) treatment, cells were incubated at 
43°C and 5 % CO： with 8 ^ M FITC-ODN for 15 hours followed by 9 hours incubation in 37T. 
The samples were measured by flow cytometry. The curves from left to right are negative control, 
37°C control and HT treatment. 
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ii) Enhanced O D N uptake by hyperthermia in MCF-7 cells was incubation time 
and concentration dependent: 
The effects of 43°C incubation time and oligodeoxynucleotide concentration 
on the cellular uptake of FITC-ODN in MCF-7 cells were investigated on MCF-7 
cells. The cells were seeded for 100,000 cells per well at 24-well plate and were 
incubated at 37°C for 24 hours. The cells were washed twice with serum free 
RPMI-1640. 
For incubation time study, 8 |^M of FITC-ODN was used in all samples 
except the negative control, which contained serum free medium only and the 
incubation temperature was 2>TC for 24 hours. For the samples designing as HT-
5，15 and 24 hours, the samples were subjected to H T at 43°C for 5, 15 and 24 
hours respectively, followed by incubating for 19, 9 and 0 hours at 37°C 
respectively, i.e. totally 24 hours were involved. For 37°C control, the incubation 
was 37°C for 24 hours. 
The mean fluorescent values for negative control, 37°C control, HT-5 hours 
sample, HT-15 hours sample and HT-24 hours sample were 4.5, 96.7, 135.7, 
203.8 and 244.3 units respectively (Figure 4.2). This result indicates that the 
enhanced O D N uptake by hyperthermia was incubation time dependent. 
For studying oligodeoxynucleotide concentration effect, all samples except 
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the negative control were incubated at 43°C for 15 hours then at 37°C for 9 hours. 
For negative control, cells were incubated in serum-free RPMI-1640 at 37°C for 
24 hours without FITC-ODN. One |iM, 2 ^ iM, 4 ^iM and 8 jdM FITC-ODN in 
serum-free RPMI-1640 were added to MCF-7 cells and measured by flow 
cytometry after the incubation. 
The mean fluorescent values for negative control, 1 ^ M, 2 ^ iM, 4 p,M and 8 
p,M samples were 3.6, 98.8, 136.5, 178.2 and 288 units respectively (Figure 4.3). 
This result indicates that the enhanced O D N uptake by hyperthermia on MCF-7 
cells was concentration dependent. 
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Samples Mean Fluorescence Value / units 
"• • 夏 
Control 4.5 
0 hour 96.7 
HT-5 hours 135.7 
HT-15 hours 203.8 
HT-24 hours 244.3 
F i g u r e 4 . 2 : The effect o f incubation time at 43°C hyperthermia on F ITC-ODN uptake o f 
MCF-7. MCF-7 cells were seeded for 100,000 cells per well at 24-well plate and were incubated at 
37°C for 24 hours. The cells were washed twice with serum free R P M M 6 4 0 . Eight ^iM of FITC-
O D N was used in all samples except the negative control, which had serum free medium only and 
the incubation temperature was 37°C for 24 hours. For the samples ofHT-5, 15 and 24 hours, they 
were subjected to HT at 43°C for 5, 15 and 24 hours respectively, followed by incubating for 19，9 
and 0 hours at 37。C respectively, i.e. totally 24 hours were involved. For 37°C control, the 
incubation was 37°C for 24 hours with 8 ( iM FITC-ODN. The samples were measured by flow 
cytometry after the incubation. The curves from left to right are negative control, 37。C control (0 
hour), HT-5 hours incubation, HT-15 hours and HT-24 hours incubation. 
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Samples Mean Fluorescence Value / units 
Control 3.6 
1 |aM 98.8 
2 ^ iM 136.5 
4 |iM 178.2 
8 ^ iM 288.0 
F i g u r e 4.3: The effect o f oligodeoxynucleotide concentration on F ITC-ODN uptake o f 
MCF-7 cells. The cells were seeded for 100,000 cells per well at 24-well plate and were incubated 
at 37°C for 24 hours. The cells were washed twice with serum free RPMI-1640. Al l samples 
except the negative control were incubated at 43°C for 15 hours then at 37。C for 9 hours. For 
negative control, cells were incubated in serum-free RPMI-1640 at 37。C for 24 hours without 
FITC-ODN. One ^ M , 2 ^ M , 4 ^iM and 8 ^ M FITC-ODN in serum-free RPMI-1640 were added to 
MCF-7 cells. The curves from left to right are negative control, 1 ^iM FITC-ODN, 2 ^ M , 4 ^ M 
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iii) Effect ofhyperthermia on O D N uptake on other cell lines: 
Three other human cancer cell lines were investigated by flow cytometry. 
They were human breast cancer cell line without estrogen receptors (MDA-MB-
231), human liver cancer cell line (HepG-2) and human colon cancer cell line 
(Caco-2). All cell lines were seeded in a 24-well plate for 100,000 cells per well 
and incubated for 24 hours at 37°C. The cells were washed twice with serum free 
RPMI-1640. Eight ^iM FITC-ODN was used in all samples except negative 
control, which only contained semm-free RPMI-1640. The incubation time for 
HT treated samples at 43°C was 15 hours while in negative control and 37°C 
control, cells were incubated at 37°C for 15 hours. 
For MDA-MB-231, the mean fluorescent values for negative control, 37°C 
control and H T group were 2.7, 74.2 and 120.1 units respectively (Figure 4.4). 
For HepG-2, the mean fluorescent values for negative control, 37°C control 
and HT group were 3.0, 42.6 and 93.3 units respectively (Figure 4.5). 
For Caco-2, the mean fluorescent values for negative control, 37°C control 
and HT group were 5.1, 67.8 and 114.0 units respectively (Figure 4.6). 
These results indicate that the effect of enhancement of O D N uptake by HT 
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V F i g u r e 4 .4 : The effect o f 43°C hyperthermia on FITC-ODN uptake o f MDA-MB-231. The 
cells were seeded for 100,000 cells per well at 24-well plate and were incubated at 37°C for 24 
hours. They were then washed twice with serum free RPMI-1640. Eight ^ M FITC-ODN was used 
in all samples except the negative control, which only contained serum-free RPMI-1640. The 
incubation time for HT-treated samples at 43°C was 15 hours while in negative control and 37°C 
control, the cells were incubated at 37°C for 15 hours. The samples were measured by flow 
cytometry after the incubation. The curves from left to right are negative control, 37°C control and 
HT treatment. 
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F i g u r e 4 .5 : The effect o f 43°C hyperthermia on FITC-ODN uptake o f HepG-2. The cells 
were seeded for 100,000 cells per well at 24-well plate and were incubated at 37。C for 24 hours. 
The cells were then washed twice with serum free RPMI-1640. Eight ^iM F ITC-ODN was used in 
all samples except the negative control, which only contained serum-free RPMI-1640. The 
incubation time for HT-treated samples at 43°C was 15 hours while in negative control and 37。C 
control, the cells were incubated at 37°C for 15 hours. The samples were measured by flow 
cytometry after the incubation. The curves from left to right are negative control, 37°C control and 
HT treatment. 
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F i g u r e 4 . 6 : The effect o f 43°C hyperthermia on F ITC-ODN uptake o f Caco-2. The cells 
were seeded for 100,000 cells per well at 24-well plate and were incubated at 37。C for 24 hours. 
The cells were then washed twice with serum-free RPMI-1640. Eight ^ M F ITC-ODN was used in 
all samples except the negative control, which only contained serum-free RPMI-1640. The 
incubation t ime for HT-treated samples at 43°C was 15 hours whi le in negative control and 37°C 
control, the cells were incubated at 37。C for 15 hours. The samples were measured by flow 
cytometry after the incubation. The curves from left to right are negative control, 37°C control and 
HT treatment. The minor peak o f spontaneous uptake curve may be due to the surrounded cells 
which were not exposed to F ITC-ODN. 
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4.3) Confocal microscopic studies: 
Cellular distribution of FITC-ODN in MCF-7 cells determined by confocal 
microscope: 
This study investigated the cellular distribution of FITC-ODN in MCF-7 
cells by confocal microscope. The excitation wavelength used was 488 nm and 
emission wavelength was 510 nm. MCF-7 cells were scanned vertically by 0.5 
i^m sections from bottom to top of the cell particles (Figure 4.7a to 4.7d). The 
typical pictures of the central optical section along the vertical axis were shown in 
Figure 4.8. 
For negative control, only serum-free RPMI-1640 medium was added and 
the cells were incubated at 37°C for 15 hours. It was then washed twice with ice 
cold PBS. The picture shows that no fluorescent signal could be detected by the 
confocal microscope, but the signal appeared after staining with Acridine Orange 
(AO) at a final concentration of 1 )uM (Figure 4.8a). 
For 37°C control, 8 jiM FITC-ODN was added in serum-free RPMI-1640 
and the cells were incubated at 37°C for 15 hours. It was then washed twice with 
ice cold PBS. From the image, it was observed that FITC-ODN had been uptaken 
mainly into the cytoplasm of the cells spontaneously and it was concentrated at 
some regions (Figure 4.8b). 
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For 43°C HT treatment, 8 p M FITC-ODN was added and incubated at 43^C 
for 15 hours. The image produced was similar to that of the 37°C control (Figure 
4.8c). The results indicate that the FITC-ODN were internalized into the 
cytoplasm and not just adhered on the cell surface in both spontaneous uptake at 
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Figure 3.5c: 
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Figure 4.7: The intracellular distribution of FITC-ODN in MCF-7 cells by confocal 
microscope. The excitation wavelength was 488 nm and emission wavelength accepted was 510 
ran. MCF-7 cells were scanned verticaUy by 0.5 fjm sections from bottom to top of the cell 
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particles. The cells were seeded for 250,000 cells per well on a round cover glass in the 6-well 
plate. They were then incubated at 37。C and 5 % CO2 for 24 hours. The cells were washed twice 
with serum-free RPMI-1640. For 37°C cntrol, 8 ^iM FITC-ODN was added in serum free RPMI-
1640 and the cells were incubated at 37°C for 15 hours. They were then washed twice with ice 
cold PBS and measured by confocal microscope (Figure 4.7a). The plate was then stained with 
Acridine Orange (AO ) at the finaI concentration o f 1 |iM (Figure 4.8b). For 43°C HT treatment, 8 
^iM F ITC-ODN was added in serum free RPMI-1640 and incubated at 43°C for 15 hours (Figure 
4.7c). The plate was then stained with Acridine Orange (AO) at a final concentration o f 1 ^ M 
(Figure 4.7d). 
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Figure 4.8: The intracellular distiibution of FITC-ODN on MCF-7 cells by confocal 
microscope. The excitation wavelength used was 488 mn and emissicm wavelength accepted was 
510nm. MCF-7 cells were scanned vertically by 0.5 \ m sections from bottom to top o f t h e cell 
particles, l ^ e typical picture of the middle axis of the cell in vertical direction was shown. The 
cells MCF-7 were seeded for 250,000 cells per well on a round cover glass in the 6-well plate. It 
was thai incubated at 3TC and 5 % CO2 for 24 hours. The cells were washed twice with serum-
free RPMI-1640. For negative control, only serum free RPMI-1640 medium was added and the 
cells were incubated at 3TC for 15 hours. It was then washed twice with ice cold PBS. The picture 
shows no fluoresc^it signal can be detected by the confocal microscope 0-eft) and it was then 
stained with Ao-idine Orange (AO) at a final concentration of 1 ^M ORight) f i g u r e 4.8a). For 
3T"C control, 8 ^M FFTC-ODN was added in smmi-jfree RPMI-1640 and the cells were incubated 
at 3 7 T for 15 hours. It was then washed twice with ice cold PBS. From the image, it was observed 
that FrrC-ODN had been uptaken mainly into the cytoplasm of the cells spontaneously and it was 
concentrated at some regirais (Left) and it was then stained with Aoidine Orange (AO) at a final 
concentration of 1 ^M (Right) (Figure 4.8b). For 43°C HT treatment, 8 ^M FITC-ODN was 
involved in serum free RPMI-1640 and incubated at 43°C for 15 hours. The image produced was 
similar to the 3TC control 0-eft) and it was then stained with Acridine Orange (AO) at a final 
concentration of 1 ^M (^ght) (Figure 4.8c). 
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4.4) Cytotoxic effect of hyperthermia on MCF-7 cells: 
M T T assay was carried out to study the cytotoxic effect of hyperthermia 
(HT) at 43。C on MCF-7 cells. The cells of20,000 cells per well were seeded in a 
96-well plate and incubated at 37°C for 24 hours. The cells were then washed 
twice with serum free RPMI-1640. 
In hyperthermia studies, 200 ^1 serum free RPMI-1640 was used in all 
samples. For negative control (0 hour control), cells were incubated at 7>TC for 24 
hours. For HT-5 hours sample, cells were incubated at 43°C for 5 hours then at 
37°C for 19 hours. These treatments were similar for HT-15 hours and HT-24 
hours test samples that the total experimental time was 24 hours for H T plus 37°C 
incubation. 
The percentage control survival rate for HT-5 hours, HT-15 hours and HT-24 
hours at 43°C hyperthermia were 90 %, 55 % and 45 % respectively (Figure 4.9). 
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F i g u r e 4 . 9 : The cytotoxic effect o f 43。C hyperthermia (HT) on MCF-7 cells in various time 
intervals. The cells o f 20,000 cells per well were seeded in a 96-well plate and incubated at 37°C 
for 24 hours. The cells were then washed twice with serum free RPMI-1640. Two hundred ^il 
serum-free RPMI-1640 was used in all samples. For negative control (0 hour control), cells were 
incubated at 37°C for 24 hours. For HT-5 hours sample, cells were incubated at 43°C for 5 hours 
then at 3TC for 19 hours. These treatments were similar for HT-15 hours and HT-24 hours test 
samples that the total experimental time was 24 hours for HT plus 37。C incubation. The 
percentage survival was determined by MTT assays. Results were means 土 SD o f 20 duplicates. 
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4.5) FITC-ODN uptake in survival cells by propidium 
iodide (PI) exclusion method for hyperthermia: 
For most of the survival cells, the membrane is integrative with full 
selectively permeable function. As a result, the cell would not uptake PI or able to 
pump out PL This is the basic mechanism ofPI exclusion method. 
The purpose of this experiment is to study the difference between adhesive 
survivial cells and dead cells in FITC-ODN uptake. Moreover, adhesive dead cells 
would be excluded from the total adhesive cells. For the suspended dead cells, 
they were removed after washing with ice-cold PBS. 
Two parameters FL1 (green) for FITC and FL3 (red) for PI uptake were 
measured simultaneously by flow cytometry. Cell density of 100,000 cells per 
well for the four cell lines; MCF-7, MDA-MB-231, Caco-2 and HepG-2, were 
seeded in a 24-well plate. The cells were incubated at 37°C and 5 % CO2 for 24 
hours. It was then washed with serum-free RPMI-1640 for two times. For 
hyperthermia treatment, 8 |aM FITC-ODN was added in serum-free RPMI-1640 
and the incubation time was 15 hours at 43°C. The incubation was 37°C for 15 
hours in negative control and 37。C control. For 37。C control, 8 |aM FITC-ODN in 
serum-free RPMI-1640 was added. For negative control, only serum-free RPMI-
1640 was added. 
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After the program W D ^ M D I 2.6 analysis, the medium to high PI uptake 
population was excluded (Figure 4.10). From the result, the mean fluorescent 
values were all slightly decreased after the PI exclusion for the four cell lines. 
However, the fold-enhanced uptake ratios were similar for MCF-7, MDA-MB-
231 and HepG-2. For Caco-2 cell line, the fold-enhanced uptake ratio was 
increased from 1.68 to 1.96 (Table 4.1). 
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Figure 4.10g: 
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Figure 4.10b 
FLl-Height(l) vs FL3-Heighti:2) 
F i g u r e 4 . 1 0 (a a n d b): Density plot of PI exclusion analysis. The x-axis is FLl-Height for FITC 
signal and the y-axis is FL3-Height for PI uptake. Figure 4.10a is 37。C for 15 hours with 8 ^iM 
FITC-ODN on MCF-7. Figure 4.10b is 43°C for 15 hours with 8 u M FITC-ODN on MCF-7. After 
the program W I N M D I 2.6 analysis, the medium to high PI uptake population was excluded. 
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Figure 4.10c: 
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Figure 4.10d: 
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F i g u r e 4 . 1 0 (c a n d d) : Density plot o f P I exclusion analysis. The x-axis is FLl-Height for FITC 
signal and the y-axis is FL3-Height for PI uptake. Figure 4.10c is 37。C for 15 hours with 8 ^iM 
FITC-ODN on MDA-MB-231. Figure 4.10d is 43°C for 15 hours with 8 ^ M FITC-ODN on 
MDA-MB-231. After the program W I N M D I 2.6 analysis, the medium to high PI uptake 
population was excluded. 
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F i g u r e 4 .10 (e a n d f): Density plot of PI exclusion analysis. The 
signal and the y-axis is FL3-Height for PI uptake. Figure 4.10e is 
FITC-ODN on Caco-2. Figure 4.10fis 43。C for 15 hours with 8 ^iM FITC-ODN on Caco-2. After 
the program W I N M D I 2.6 analysis, the medium to high PI uptake population was excluded. 
x-axis is FLl-Height for FITC 
37°C for 15 hours with 8 |_iM 
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Figure 4.10h: 
FLl-Height(l) vs FL3-Height(2) 
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F i g u r e 4 . 1 0 (g a n d h): Density plot o f P I exclusion analysis. The x-axis is FLl-Height for FITC 
signal and the y-axis is FL3-Height for PI uptake. Figure 4.10g is 37。C for 15 hours with 8 ^iM 
FITC-ODN on HepG-2. Figure 4.10h is 43。C for 15 hours with 8 ^iM FITC-ODN on HepG-2. 
After the program W D ^ M D I 2.6 analysis, the medium to high PI uptake population was excluded. 
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Mean Fluorescent Values (MFV) PI exclusion  
Cells: control Ij^C \43^C |igfl"V? control \3rC \43'C \Ratio 
MCF-7 5.4" 96.9 168.2 1.74— 5.4 89.6 157.1 1.75 
MDA-MB-231 2.7~ 74.2 120.1" 1.62— 2.7 723 111.9 1.55 
Caco-2 5.r 67.8 114 1.68— 4.3 54.f 106 1.96 
HepG-2 3| 42.6| 93.3| 2.19| 2.9| 4L4| 9Q.4| 2.18 
T a b l e 4 .1 : F ITC-ODN uptake in survival cells by propidium iodide (PI) exclusion method for 
hyperthermia at 43°C. Two parameters FL1 (green) for FITC and FL3 (red) for PI uptake were 
measured simultaneously by flow cytometry. Cell density of 100,000 cells per well for the four 
cell lines; MCF-7, MDA-MB-231, Caco-2 and HepG-2, were seeded in a 24-well plate. The cells 
were incubated at 37°C and 5 % CO2 for 24 hours. They were then washed with serum-free RPMI-
1640 twice. For hyperthermia treatment, 8 |iM FITC-ODN was added in serum-free RPMI-1640 
and the incubation time was 15 hours at 43°C. The incubation was 37°C for 15 hours in negative 
control and 37°C control. For 37°C control, 8 ^iM FITC-ODN in serum free RPMI-1640 was 
added. For negative control, only serum-free RPMI-1640 was added. After the program W I N M D I 
2.6 analysis, the medium to high PI uptake population (dead cells) was excluded. The 37 D C 
, means 37°C, HT means 43°C hyperthermia, the ratio represents fold-enhancement o f FITC-ODN 
uptake and is equal to M F V 43°C / MFV37°C. 
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4.5) Discussion: 
Hyperthermia is one of the interesting research areas in cancer therapy. It 
involves the use of heat at higher than 37°C temperature, such as, 43°C to treat 
tumor cells for described time periods. Hyperthermia at 43°C increased the 
cellular uptake of doxorubicin in the nuclei of two esophageal squamous cell 
carcinoma cell lines, TE-2 and TE-2 (Kawai et. al, 1997). In rodent model, 
Sprague-Dawley rats, hyperthermia at 43°C exhibited increased doxorubicin 
concentrations for all intraabdominal tissues (Jacquet et. al., 1998). This chapter 
investigated the effect of hyperthermia at 43°C on cellular uptake of 
oligodeoxynucleotide. 
W e have observed that (1) when MCF-7 cells were incubated with 8 ^ M 
FITC-ODN in serum free RPMI-1640 medium in hyperthermia at 43°C for 15 
、 hours, the oligodeoxynucleotide uptake was enhanced by 3-fold on average; (2) 
this hyperthermia enhanced uptake was incubation time and oligonucleotide 
concentration dependent; (3) the enhancing effects of hyperthermia on the FITC-
O D N uptake were found to be similar in HepG-2, MDA-MB-231 and Caco-2 
cells as in that of MCF-7 cells; (4) by confocal microscope observations, it was 
proved that the FITC-ODN was delivered into the cells by hyperthermia as well as 
by Lipofectin, and the O D N was not just adhered on the cell surface. From the 
images of hyperthermia and 37°C control, it is probable that the O D N might be 
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uptaken through endocytotic pathway as the fluorescence was concentrated in 
some regions at the cytoplasm for both H T and 37。C control. Compared with the 
data obtaining from Lipofectin-aided sample in which the fluorescence was found 
to be widely distributed at the cytoplasm (Figure 3.6 and Figure 4.8), it can be 
concluded that Lipofectin-aided transfection may involve different pathways. 
From PI exclusion experiment, we have shown that the hyperthermia 
enhanced O D N uptake occurred in adhesive survivial cells. It is not due to the 
adhesive dead cells which we thought may absorb larger amount of FITC-ODN. 
The fold-enhancement values (ratio) were not changed significantly after the 
PI exclusion method which excludes dead cells from the total adhesive cells 
measured. 
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Chapter 5, 
The antiproliferative effects of antisense molecules against 
Glut-1 and 5 on MCF-7 cells transfected by Lipofectin 
5.1) Introduction: 
Cellular glucose uptake is mediated by facilitative glucose transporters. 
These transporters show tissue-specific distribution, but overexpression of 
isoforms type 1 and type 3 have been reported in many kinds of human cancers. 
Moreover, some tumors deviate from the normal tissue in distribution of glucose 
transporters, e.g. GLUT-5 is absent in normal breast tissue but it is expressed in 
human breast cancer (Zamora-Leon et. al., 1996). Some previous studies have 
targeted on the inhibition of glucose transporters to suppress the proliferation of 
tumor cells. However, inhibitors of glucose uptake have severe side effects on 
patients and their actions are also not specific. 
Antisense strategy is a developing novel technique to inhibit gene 
expression specifically. The strategy makes use of modified antisense molecules, 
mostly oligodeoxynucleotide (ODN), which has a sequence complementary to 
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part of the target D N A or m R N A , to prevent transcription and/or translation. 
Recently, human clinical trial of antisense treatment against oncogene BCL-2 on 
patients bearing late stage cancer is in progress and the results in the early report 
are encouraging (Webb et. al, 1997). 
This chapter studies the effect of phosphorothioated antisense 
oligodeoxynucleotides against GLUT-1 and GLUT-5 on breast tumor MCF-7 
cells. Lipofectin was used as a carrier. The human breast cancer cell line MCF-7 
was studied because it expresses GLUT-5 and overexpresses GLUT-1. The sense 
control is used in this experiment, which is used to exclude the cytotoxic effect of 
Lipofectin and non-specific effect of antisense molecules. 
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5.2) The growth curve ofMCF-7cells: 
Human breast cancer MCF-7 cells were seeded in a 96-well plate at 20,000 
cells per well and incubated in 37°C with 5 % CO2 for 24 hours. It is for the cells 
to adhere onto the bottom of the wells. The medium used was RPMI-1640 with 10 
% fetal bovine serum. The percentage confluence was determined by 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolmm bromide (thiazolyl blue, MTT) 
assay. 
From the result, the doubling time for the growth of MCF-7 cells is roughly 
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F i g u r e 5 .1 : The growth curve o fMCF-7 cells. The cells were seeded in a 96-well plate for 
20,000 cell/well and incubated in 3TC with 5 % CO2 for 24 hours. The medium used was RPMI-
1640 with 10 % fetal bovine serum. The medium was exchanged after 48 hours. The percentage 
confluence was determined by MTT assay and 100 % confluence was determined by light 
microscope. Results were means 士 SD o f 10 duplicates. 
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5.3) The calibration of MTT assay: 
M T T assay was used to measure the amount of survival cells with M T T 
reagent. The mechanism is based on the reducing power of mitochondria in 
surviving cells. 
M T T molecule first penetrates the plasma membrane and reaches the active 
mitochondria. This dye is then reduced by the active mitochondria and forms dark 
blue crystal. A suitable solvent，such as 0.04N HC1 acidified isopropanol, can 
dissolve the crystal and produce a purple coloration that is proportional to the 
amount of dark purple crystal formed. Followed by spectrophotometer 
measurement at OD540, the amount of survival cells can be determined. 
MCF-7 cells were seeded in a 96-well plate for indicated cell densities in 
RPMI-1640 medium containing 10 % fetal bovine serum. They were incubated in 
a 5 % CO2 incubator for 24 hours. M T T assay was then carried out and the 
dissolved dye product was measured spectrophotometrically at O D 540 (Figure 
5.2). 
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Figure 5.2: 
for indicated cell 
1640 and 10 % 
MTT assay calibration for MCF-7 cells. The cells were seeded in a 96-well plate 
densities. The cells were incubated in 37°C and 5 % CO2 incubator with RPMI-
fetal bovine serum for 24 hours. MTT assay was then carried out and was 
measured spectrophotometrically at O D 540. Results were means 土 SD o f 10 duplicates. 






5.4) The effect of antisense Glut-1 concentration without 
Lipofectin on MCF-7 cells: 
This part investigated the effect of antisense Glut-1 on MCF-7 cells without 
Lipofectin. The conditions used were similar to those used in the spontaneous 
uptake of antisense oligodeoxynucleotide (ODN) as described in Chapter 3. 
The antiproliferative effect of antisense Glut-1 without Lipofectin was 
concentration dependent and the sense O D N control exhibited lower effect than 
antisense O D N (Figure 5.3). At antisense Glut-1 concentration of 20 ^M, the 
difference between antisense and sense was greatest which was about 20 % 
difference in cellular proliferation. The difference was statistically significant. 
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F i g u r e 5.3: The effect o f antisense Glut-1 on MCF-7 without Lipofectin. The cells were 
seeded in a 96-well plate at 20,000 cells per well. They were then incubated in 3TC and 5 % CO2 
for 24 hours. The medium was removed and cells were washed with serum free RPMI-1640 twice. 
The cells were then incubated with antisense and sense Glut-1 for indicated concentrations in 
serum-free RPMI-1640 for 24 hours in 37°C. For negative control, only serum-free RPMI-1640 
was added. The medium was then removed and serum-containing medium was added. MTT assay 
was carried out when the negative control was 100 % confluent determined by light microscope, it 
was at about 65 hours after further incubation. AS means antisense and S means sense control. The 
antiproliferative effect o f antisense Glut-1 is concentration dependent and the sense control has 
lower antiproliferative effect than that o f antisense. Results were means 土 SD o f 5 duplicates. 





































5.5) The effect of antisense Glut-1 concentration with 
Lipofectin on MCF-7 cells: 
This part investigated the concentration effect of antisense Glut-1 with 
Lipofectin on MCF-7 cells. 
The antiproliferative effect of antisense Glut-1 with Lipofectin was also 
concentration dependent and the sense O D N control exhibited lower effect than 
antisense O D N . The maximum antiproliferative effect under this condition was 34 
% when the cells were treated with antisense Glut-1 at 5 jiM (Figure 5.4). 
Moreover, the potency of antisense Glut-1 was enhanced by Lipofectin-aided 
transfection when compared with that of spontaneous uptake without Lipofectin 
(Figure 5.3). A l t h o u g h , L i p o f e c t i n a l o n e has cytotoxic e f f e c t on MCF-7 c e l l s 
under high concentration (Figure 3.7), the cytotoxic effect can be excluded by the 
sense control which also involve same amount of Lipofectin. 
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F i g u r e 5.4: The effect of concentration o f antisense Glut-1 on MCF-7 cells with Lipofectin. 
The cells were seeded in a 96-well plate at 20,000 cells per well. They were then incubated at 37°C 
and 5 % CO2 for 24 hours. The medium was removed and cells were washed with serum free 
R P M M 6 4 0 twice. The cells were then transfected with different concentrations o f antisense (AS) 
and sense (S) Glut-1 for indicated concentrations by Lipofectin for 5 hours in 37°C. For negative 
control, only serum-free RPMI-1640 was added. The medium was then removed and serum-
containing medium was added. MTT assay was carried out when the negative control was 100 % 
confluent, it was at about 65 hours after further incubation. The w/w ratio o f antisense or sense to 
Lipofectin was 1:1. Results were means 土 SD of 5 duplicates. 
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5.6) The effect of antisense Glut-5 concentration without 
Lipofectin on MCF-7cells: 
This part investigated the effect of antisense Glut-5 concentration without 
Lipofectin on MCF-7 cells. 
The antiproliferative effect of antisense Glut-5 without Lipofectin was 
concentration dependent and the effect of sense 〇DN control was lower than that 
of antisense O D N (Figure 5.5). However, the antiproliferative effect of antisense 
Glut-5 without Lipofectin was not as specific as that of Glut-1 and was less potent 
than that of antisense Glut-1 (Figure 5.3). 
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F i g u r e 5 .5 : The effect o f antisense Glut-5 on MCF-7 cells without Lipofectin. The cells 
were seeded in a 96-well plate at 20,000 cells per well. They were then incubated in 3TC and 5 % 
CO2 for 24 hours. The medium was removed and cells were washed with semm free RPMI-1640 
twice. The cells were then incubated with antisense and sense Glut-5 for indicated concentrations 
in serum-free RPMI-1640 for 24 hours at 37。C. For negative control, only serum-free RPMI-1640 
was added. The medium was then removed and serum-containing medium was added. MTT assay 
was carried out when the negative control was 100 % confluent, it was at about 65 hours after 
further incubation. The antiproliferative effect o f antisense Glut-5 is concentration dependent and 
the sense control has lower antiproliferative effect than that o f antisense. Results were means 土 SD 

































5.7) The effect of antisense Glut-5 concentration with 
Lipofectin on MCF-7cells: 
This part investigated the concentration effect of antisense Glut-5 with 
Lipofectin on MCF-7 cells. 
The antiproliferative effect of antisense Glut-5 with Lipofectin was also 
concentration dependent and the effect of sense O D N control was lower than that 
of antisense O D N . The maximum antiproliferative effect under this condition was 
30 % when the cells were treated with antisense Glut-5 at 10 ^ iM (Figure 5.6). 
The antiproliferative effect of antisense Glut-5 was enhanced by Lipofectin when 
compared with spontaneous uptake (Figure 5.5). However, it was less potent than 
that of antisense Glut-1 with Lipofectin-aided transfection (Figure 5.4). 
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Figure 5.6: The effect o f concentration o f antisense Glut-5 on MCF-7 cells with Lipofectin. 
The cells were seeded in a 96-well plate at 20,000 cells per well. They were then incubated in 
370c and 5 % CO2 for 24 hours. The medium was removed and cells were washed with serum free 
RPMI-1640 twice. The cells were then transfected with different concentrations o f antisense (AS) 
and sense (S) Glut-5 for indicated concentrations by Lipofectin for 5 hours in 37。C. For negative 
control，only serum-free RPMI-1640 was added. The medium was then removed and serum-
containing med ium was added. MTT assay was carried out when the negative control was 100 % 
confluent, it was at about 65 hours after further incubation. The w/w ratio o f antisense or sense to 
Lipofectin was 1:1. Results were means 土 SD o f 5 duplicates. 
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5.8) The effect of transfection time of antisense Glut_l on 
MCF'7cells: 
This part investigated the effect of transfection time of antisense Glut-1 with 
Lipofectin on MCF-7 cells. 
The antiproliferative effect of antisense Glut-1 with Lipofectin was 
transfection time dependent and the effect of sense Glut-1 control was lower than 
that of antisense Glut-1 (Figure 5.7). 
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Figure 5.7: The effect o f transfection time of antisense Glut-1 on MCF-7 cells. The cells 
were seeded in a 96-well plate at 20,000 cells per well. They were then incubated in 37。C and 5 % 
CO2 for 24 hours. The medium was removed and cells were washed with serum free RPMI-1640 
twice. The cells were then transfected with antisense (AS) and sense (S) Glut-1 by Lipofectin for 
indicated hours. For negative control, only serum-free RPMI-1640 was added. The medium was 
< then removed after the indicated transfection time periods and serum-containing medium was 
added. MTT assay was carried out when the negative control was 100 % confluent, it was at about 
65 hours after fiirther incubation. The antisense and sense concentration was 2.5 ^ M . The w/w 
ratio of antisense or sense to Lipofectin was 1:1. Results were means 士 SD o f 5 duplicates. 
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5.9) The effect of transfection time of antisense Glut-5 on 
MCF-7cells: 
This part investigated the effect of the Lipofectin transfection time of 
antisense Glut-5 on MCF-7 cells. 
The antiproliferative effect of antisense Glut-5 with Lipofectin was also 
transfection time dependent and the effect of sense control was lower than that of 
antisense (Figure 5.8). However, the effect was less potent than that of antisense 
Glut-1 (Figure 5.7). 
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Figure 5.8: The effect o f transfection time o f antisense Glut-5 with Lipofectin on MCF-7 
cells. The cells were seeded in a 96-well plate at 20,000 cells per well. They were then incubated 
in 37°C and 5 % CO2 for 24 hours. The medium was removed and cells were washed with serum 
free RPMI-1640 twice. The cells were then transfected with antisense (AS) and sense (S) Glut-5 
by Lipofectin for indicated hours. For negative control, only serum-free RPMI-1640 was added. 
The medium was then removed and serum-containing medium was added. MTT assay was carried 
out when the negative control was 100 % confluent，it was at about 65 hours after further 
incubation. The antisense and sense concentration was 2.5 j iM. The w/w ratio o f antisense or sense 
to Lipofectin was 1:1. Results were means 士 SD of 5 duplicates. 
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5.10) The effect oftransfection time of antisense Glut-5 for 
higher concentration on MCF-7 cells: 
As the antiproliferative effect of antisense Glut-5 on MCF-7 cells was not 
very potent even after 24 hours transfection time (Figure 5.8). This part 
investigated the Lipofectin transfection time effect of antisense Glut-5 at higher 
concentration on MCF-7 cells. 
The antiproliferative effect of antisense Glut-5 was enhanced 2 folds by 
increasing the antisense concentration from 2.5 ^ M (Figure 5.8) to 10 ^ M in 
MCF-7 cells treated under 24-hour transfection time(Figure 5.9). 





Figure 5.9: The effect of transfection time of antisense Glut-5 for higher concentration on 
MCF-7 cells. The cells were seeded in a 96-well plate at 20,000 cells per well. They were then 
incubated in l>TC and 5 % CO2 for 24 hours. The medium was removed and cells were washed 
with serum free RPMI-1640 twice. The cells were then transfected with antisense (AS) and sense 
(S) Glut-5 by Lipofectin for indicated hours. For negative control, only serum-free RPMI-1640 
was added. The medium was then removed and serum-containing medium was added. MTT assay 
was carried out when the negative control was 100 % confluent, it was at about 65 hours after 
further incubation. The antisense and sense concentration vvas 10 j iM. The w/w ratio o f antisense 



































5.11) The effect of antisense Glut-1 to Lipofectin (w/w) ratio 
on MCF-7 cells: 
This part investigated the effect of antisense to Lipofectin (w/w) ratio for 
antisense Glut-1 on MCF-7 cells. 
Increasing the antisense to Lipofectin (w/w) ratios from 1:1 to 1:4 enhanced 
the antiproliferative effect of antisense Glut-1 (Figure 5.10). Only 40 % of cells 
survival was observed in cells treated by antisense Glut-1 to Lipofectin w/w ratio 
of 1:4. In the sense control groups, the survival rates remained high at 80 - 90 % 
in cells treated by sense control to Lipofectin with w/w ratio from 1:1 to 1:4. 
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Figure 5.10: The effect o f antisense Glut-1 to Lipofectin w/w ratio on MCF-7 cells. The cells 
were seeded in a 96-well plate at 20,000 cells per well. They were then incubated in 37°C and 5 % 
CO2 for 24 hours. The medium was removed and cells were washed with serum free RPMI-1640 
twice. The cells were then transfected with antisense (AS) and sense (S) Glut-1 by Lipofectin for 
indicated ratios. For negative control, only serum-free RPMI-1640 was added. The medium was 
then removed after the transfection time period and serum-containing medium was added. MTT 
assay was carried out when the negative control was 100 % confluent, it was at about 65 hours 
after further incubation. The antisense and sense concentration was 2.5 fiM. The transfection time 
was 15 hours. Results were means ± SD of 5 duplicates. 



































5.12) The effect of antisense Glut-1 to Lipofection (w/w) 
ratiofor longer transfection time on MCF-7 cells: 
This part investigated the effect of antisense to Lipofectin w/w ratio for 
antisense Glut-1 on MCF-7 cells for longer transfection time. 
When the transfection time was increased from 15 hours to 24 hours, the 
effect of antisense Glut-1 was enhanced from 39 % growth suppression (Figure 
5.10) to 55 % (Figure 5.11) for antisense to Lipofectin ratio 1:2. However, for the 
ratio 1:4, the effect of antisense Glut-1 was not further increased by the longer 
transfection time. It seems that the antisense effect may be saturated. Moreover, 
the sense effects were increased for all the three ratios for the longer transfection 
time. It should be noted that when cells were treated by sense control : Lipofectin 
(w/w) ratio of 1:4 for 15 hours, the survival rate remained high at 84 % (Figure 
5.10) but when they were treated for 24 hours, only 51 % survival rate was 
observed. 
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Figure 5.11: The effect o f antisense to Lipofectin w/w ratio for antisense Glut-1 on MCF-7 
for longer transfection time. The cells were seeded in a 96-well plate at 20,000 cells per well. They 
were then incubated in 37。C and 5 % CO2 for 24 hours. The medium was removed and cells were 
washed with serum free RPMI-1640 twice. The cells were then transfected with antisense (AS) 
and sense (S) Glut-1 by Lipofectin for indicated ratios. For negative control, only serum-free 
RPMI-1640 was added. The medium was then removed and serum-containing medium was added. 
MTT assay was carried out when the negative control was 100 % confluent, it was at about 65 
hours after further incubation. The antisense and sense concentrations were 2.5 f iM and the 
transfection time was extended to 24 hours. Results were means 土 SD o f 5 duplicates. 
























5.13) The effect of antisense Glut-5 to Lipofectin (w/w) ratio 
onMCF'7cells: 
This part investigated the effect of antisense to Lipofectin w/w ratio for 
antisense Glut-5 on MCF-7 cells. 
As antisense Glut-1 in the similar experiment, the results indicate that 
increase the antisense Glut-5 to Lipofectin ratios from 1:1 to 1:4 enhanced the 
antiproliferative effect of antisense Glut-5 (Figure 5.12). However, it should be 
noted that the antiproliferative effect of antisense Glut-5 was less than that of 
antisense Glut-1. For cells treated with 2.5 ^iM antisense Glut-1, 30 - 60 % 
suppression of survival rates were always observed (Figure 5.10), whereas only 
20 - 55% suppression of survival rates were found in antisense Glut-5 treated 
groups (Figure 5.12). Moreover, when 2.5 i^M of antisense Glut-5 were used, 
only the antisense to Lipofectin w/w ratio of 1:4 group could exhibit better 
antiproliferative effect under 15 hours transfection time (Figure 5.12). 
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Figure 5.12: The effect o f antisense Glut-5 to Lipofectin w/w ratio on MCF-7 cells. The cells 
were seeded in a 96-well plate at 20,000 cells per well. It was then incubated in 3TC and 5 % CO2 
for 24 hours. The medium was removed and cells were washed with serum free RPMI-1640 twice. 
The cells were then transfected with antisense (AS) and sense (S) Glut-5 by Lipofectin for 
indicated ratios. For negative control, only serum-free RPMI-1640 was added. The medium was 
then removed after the transfection and serum-containing medium was added. MTT assay was 
carried out when the negative control was 100 % confluent, it was at about 65 hours after further 
incubation. The antisense and sense concentration was 2.5 ^ M and the transfection time was 15 
hours. Results were means 土 SD of 5 duplicates. 
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In chapters 3 and 4, we have studied the cellular uptake of fluorescein 
labelled antisense oligodeoxynucleotide in conditions of spontaneous uptake, 
Lipofectin-aided transfection and hyperthermia enhancement. In this chapter, 
M T T assays for antisense Glut-1 and Glut-5 on MCF-7 cells was carried out to 
study the antiproliferative effects of these antisense molecules. MCF-7 cells 
express Glut-5 that is absent in normal breast tissue, and overexpress Glut-1. 
W e have found that (1) antisense Glut-1 and Glut-5 showed antiproliferative 
effect on cell line MCF-7, with or without Lipofectin; (2) the effect of antisense 
Glut-1 was more potent than that of antisense Glut-5; (3) antisense Glut-1 and 
Glut-5 exhibited higher antiproliferative effect than that of sense control. Sense 
control was used to exclude non-specific effect of antisense molecules and the 
cytotoxic effect of Lipofectin alone; (4) Lipofectin-aided transfection could 
enhance the potency of both antisense Glut-1 and Glut-5. This is because the 
uptake of antisense O D N was enhanced by Lipofectin, which has been shown in 
chapter 3; (5) the effects of antisense Glut-1 and Glut-5 with Lipofectin were 
concentration dependent, transfection time dependent and O D N to Lipofectin w/w 
ratio dependent. 
In Lipofectin-aided transfection, increase both antisense concentration, 
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transfection time and / or antisense to Lipofectin w/w ratio, can enhance the 
antiproliferative effect of antisense Glut-1 and 5. As a result, these three factors 
should be optimized, such that the antisense effect is more specific and potent. 
Under the present experimental conditions on MCF-7 cells, we have found 
that antisense Glut-1, at a concentration of 2.5 ^ M with the Lipofectin 
transfection time as 15 hours and the antisense to Lipofectin ratio is 1:4，exhibited 
60 % suppression in growth and the sense control exhibited only 16 % 
suppression, which may be due to non-specific antisense effect or cytotoxic effect 
of Lipofectin (Figure 5.10). 
For antisense Glut-5, similar phenomenon has been observed that at a 
concentration of 2.5 ^ M with 15 hours Lipofectin transfection time and the 
antisense to Lipofectin ratio is up to 1:4，antisense Glut-5 exhibited 54 % 
suppression in growth and the sense control exhibited only 28 % suppression 
(Figure 5.12). 
It was reported that the most effective Lipofectin transfection can be 
achieved when the positive-to-negative molar charges ratio between 
phosphorothioated antisense molecule (negative) and D O T M A (Lipofectin) 
(positive) is about 1 to 1 (Hartmann et. al., 1998). This molar ratio is roughly 
equal to the weight to weight (w/w) ratio of 1:4 tol:5 of 〇DN to Lipofectin used 
in our studies. 




Combined treatment is the combination of two or more individual treatments 
in order to reduce the dose of individual treatment, such that the toxic side effect 
of each individual treatment can be minimized. One famous example is the 
cocktail treatment for AIDS by Professor David Ho. The effect of combined 
treatment can be additive such that the total effect is equal to the sum of 
individual effects. It also can be synergistic such that the combined effect is larger 
than the sum of individual effects from each component. However, it may also be 
partially additive, i.e. the combined effect is less than the sum of individual 
effects. This may be due to the fact that both individual agents exhibit their effect 
by the same mechanism. 
It was suggested that the combined treatment between hyperthermia and 
radiation or chemotherapy may have better effect in cancer therapy (Gillette, 
1984). It is because the amount of chemical drugs or the dose of radiation can be 
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reduced if hyperthermia is also used. So, many serious side effects from 
chemotherapy and radiotherapy can be reduced. Antisense is a new concept for 
cancer therapy. There are accumulating evidence showing the potential of this 
concept. In chapter 4，we have shown that hyperthermia at 43°C can enhance the 
cellular uptake ofFITC labeled antisense oligodeoxynucleotide on MCF-7, M D A -
MB-231, Caco-2 and HepG-2 cells. Moreover, hyperthermia itself has antitumor 
effect under the present experimental conditions. As a result, we believe that the 
experiment must be continued to study the cellular effect of the combined 
treatment between hyperthermia and antisense. 
In this chapter, the effect of combined treatment between hyperthermia and 
antisense was studied. It was also compared with combined treatment between 
antisense Glut-1 and Glut-5. Moreover, the chronic effect of hyperthermia alone 
for shorter incubation period at 43°C was also investigated. 
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6.2) The effect of combined treatment of antisense Glut-1 
combined with antisense Glut-5 on MCF-7 cells: 
This part investigated the effect of combined treatment between antisense 
Glut-1 and Glut-5 on MCF-7 cells. 
The effect of combined treatment between Glut-1 and Glut-5 was only 
partially additive because the overall effect is less than the sum of individual 
components (Figure 6.1). The growth suppression of antisense Glut-1 was 39 % 
and that for antisense Glut-5 was 28 %, however, the combined effect was 46 %, 
which is less than the sum of individual effects. This may be due to the fact that 
both treatments exert their effects by the same mechanism, namely lowering the 
expression of glucose transporters levels in the cells and the suppression of the 
supply of glucose in the cells may be compensated by other nutrients. This 
possibility awaits further investigation. 
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F i g u r e 6.1: The effect of combined treatment between antisense Glut-1 and Glut-5 on MCF-7 
cells. The cells were seeded in a 96-well plate at 20,000 cells per well. They were then incubated 
in 37°C and 5 % CO2 for 24 hours. The medium was removed and cells were washed with serum 
free RPMI-1640 twice. The cells were then transfected with antisense Glut-1 and 5 by Lipofectin 
for 24 hours. For negative control, only serum-free RPMI-1640 was added. The medium was 
removed after the transfection and serum-containing medium was added. MTT assay was carried 
out when the negative control was 100 % confluent, it was at about 65 hours after further 
incubation. The antisense (AS) and sense (S) concentration was 2.5 ^ M for both Glut-1 and 5. For 
combined treatment, 2.5 ^iM Glut-1 and 2.5 ^iM Glut-5 were added. The w/w ratio of antisense or 
sense to Lipofectin was 1:1. Results were means 土 SD of 5 duplicates. 
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6.3) The chronic effect of hyperthermia for 5 hours on 
MCF'7cells: 
This part investigated the chronic effect of hyperthermia for 5 hours on 
MCF-7 cells. 
In MCF-7 cells treated with hyperthermia at 43°C for 5 hours and then at 
37°C for 19 hours, only 10 % suppression of cell proliferation was observed 
compared with its control. But for 65 hours further incubation time periods at 
37°C, the antiproliferative effect is 51 % compared with control (Figure 6.2). This 
may be due to the hyperthermia induced change(s) in the cells which may result in 

























Further incubation time (hour) 
Figure 6.2: The chronic effect ofhyperthermia on MCF-7 cells. The cells were seeded in a 96-well 
plate at 20,000 cells per well. They were then incubated in 37°C and 5 % CO2 for 24 hours. The 
cells were treated with 43。C for 5 hours followed by 37°C for indicated time intervals. For 
negative control, the cells were incubated in 37°C during the experiment. MTT assay was carried 
out to measure the percentage control cell proliferation. The treatment of hyperthermia at 43°C for 
5 hours followed by incubation at 37。C for 65 hours could inhibit cellular proliferation. Results 
were means 土 SD o f20 duplicates. 
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6.4) The effect of combined treatment between antisense 
Glut-1 and hyperthermia on MCF-7 cells: 
This part investigated the effect of combined treatment between antisense 
Glut-1 and hyperthermia on MCF-7 cells. 
The effect of combined treatment between antisense Glut-1 and hyperthermia 
was additive. The overall effect on suppression of proliferation rate was equal to 
the sum of individual treatments (Figure 6.3). This result may imply that 
antisense Glut-1 treatment and hyperthermia treatment exert their antiproliferative 
effect on MCF-7 cells by different mechanisms. 
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Figure 6.3:The effect o f combined treatment between antisense Glut-1 and hyperthermia on 
MCF-7 cells. The cells were seeded in a 96-well plate at 10,000 cells per well. They were then 
incubated in 37°C and 5 % CO2 for 24 hours. The medium was removed and cells were washed 
with serum free RPMI-1640 twice. For antisense Glut-l+HT treatment, the cells were then 
incubated with antisense Glut-1 in serum free medium at 43。C for 5 hours. For antisense GIut-1 
treatment, the cells were incubated with antisense Glut-1 in serum free medium at 37。C for 5 
hours. In HT treatment, the cells were treated at 43。C for 5 hours in serum free RPMI-1640 
without antisense Glut-1. For negative control, only serum-free RPMI-1640 was added and the 
cells were incubated at 37°C. The double serum medium (20 % fetal bovine serum in RPMI-1640) 
was then added such that the final senim level was 10 %. The cells were then incubated in 37°C 
incubator with 5 % CO2 level. MTT assay was carried out after 65 hours further incubation time. 
The antisense concentration was 8 |iM. Results were means 士 SD of 5 duplicates. 
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6.5) The net effect of antisense Glut-1 in combined 
treatment between hyperthermia and antisense Glut-1 on 
MCF'7 cells: 
This part investigated the net effect of antisense Glut-1 in combined 
treatment between antisense Glut-1 and hyperthermia on MCF-7. 
The experimental procedure was the same as that of Figure 6.3. The bar 37 
represents Glut-1 at 37。C，the calculation is: (OD540 of Glut-1) / (OD540 of 
negative control)X100 %. The bar H T represents Glut-1 + HT, the calculation is: 
(OD540 of Glut-l+HT) / (OD540 ofHT)X100 %. 
The net effect of antisense Glut-1 is enhanced by hyperthermia under the 
present calculation method, which excludes the antiproliferative effect of 
hyperthermia alone. There are about 16 % (i.e. 85 % - 96 % ) enhancement for 
antisense Glut-1 by hyperthermia (Figure 6.4). 
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Figure 6.4: The net effect o f antisense Glut-1 in combined treatment between antisense Glut-1 and 
hyperthermia in MCF-7 cells. The experimental procedure was the same as that o f Figure 6.3. The 
bar 37 represents Glut-1 at 37°C, the calculation is: (OD540 of Glut-1) / (OD540 of negative 
control) X100 %. The bar HT represents Glut-l+HT, the calculation is: (OD540 ofGlut-l+HT) / 
(OD540 of HT) X100 %. The net effect o f antisense Glut-1 is enhanced by hyperthermia. Results 
were means 土 SD o f 5 duplicates. 






































6.6) The effect of combined treatment between antisense 
Glut'5 and hyperthermia on MCF-7cells: 
This part investigated the effect of combined treatment between antisense 
Glut-5 and hyperthermia on MCF-7 cells. 
The effect of combined treatment between antisense Glut-5 and 
hyperthermia was also additive. As the overall suppressive effect on proliferation 
rate was equal to the sum of individual treatments (Figure 6.5). This result may 
again imply that antisense Glut-5 treatment and hyperthermia treatment exert their 
antiproliferative effects on MCF-7 cells by different mechanisms. 
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Control HT Glut-5 Glut-5+HT 
Figure 6.5: The effect o f combined treatment between antisense Glut-5 and hyperthermia on 
MCF-7 cells. The cells were seeded in a 96-well plate at 10,000 cells per well. They were then 
incubated in 37°C and 5 % CO2 for 24 hours. The medium was removed and cells were washed 
with serum free RPMI-1640 twice. For antisense Glut-5+HT treatment, the cells were then 
incubated with antisense Glut-5 in serum free medium at 43。C for 5 hours. For antisense Glut-5 
treatment, the cells were incubated with antisense Glut-5 in serum free medium at 3TC for 5 
hours. In HT treatment, the cells were treated at 43°C for 5 hours in serum free medium without 
antisense Glut-5. For negative control, only serum-free RPMI-1640 was added and the cells were 
incubated in 37°C. The double serum medium (20 % fetal bovine serum in RPMI-1640) was then 
added such that the final serum level was 10 %. The cells were then incubated in 37°C incubator 
with 5 % CO2 level. MTT assay was carried out after 65 hours further incubation time. The 
antisense concentration was 8 ^iM. Results were means 土 SD of 5 duplicates. 
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6.7) The net effect of antisense Glut-5 in combined 
treatment between hyperthermia and antisense Glut-5 on 
MCF'7cells: 
This part investigated the net effect of antisense Glut-5 in combined 
treatment between antisense Glut-5 and hyperthermia on MCF-7 cells. 
The experimental procedure was the same as that of figure 6.5. The bar 37 
represents Glut-5 at 2>TC, the calculation is: (OD540 of Glut-5) / (OD540 of 
negative control) X100 %. The bar H T represents Glut-5+HT, the calculation is: 
(OD540 ofGlut-5+HT)/(OD540 ofHT)X100 %. 
The net effect of antisense Glut-5 could not be enhanced by hyperthermia 
under the present calculation method, which excludes the antiproliferative effect 
of hyperthermia alone (Figure 6.6). 
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Control 37 HT 
Figure 6.6: The net effect of antisense Glut-5 in combined treatment between antisense Glut-5 and 
hyperthermia in MCF-7 cells. The experimental procedure was the same as that o f figure 6.5. The 
bar 37 represents Glut-5 at 2>TC, the calculation is: (OD540 of Glut-5) / (OD540 of negative 
control) X100 %. The bar HT represents Glut-5+HT, the calculation is: (OD540 ofGlut-5+HT) / 
(OD540 ofHT)X100 %. Results were means ± SD o f5 duplicates. 
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In this chapter, we have studied the effect of combined treatment of 
hyperthermia and antisense Ghit-1 or Glut-5, as well as the combined effect of 
antisense Glut-1 and Glut-5. Since hyperthermia alone has some extent of 
antitumor effect clinically and it was found by us that hyperthermia can enhance 
the cellular uptake of antisense phosphorothioated oligodeoxynucleotide in 
chapter 4 of this thesis, it is therefore reasonable to examine whether the 
combination of treatment of hyperthermia and antisense can give better 
antiproliferative effect on tumor cells. 
In this chapter, we conclude that (1) the effect of combined treatment 
between antisense Glut-1 and antisense Glut-5 is only partially additive; (2) the 
effect of combined treatment between hyperthermia and antisense Glut-1 or 
antisense Glut-5 is both additive; (3) the net effect of antisense Glut-1 is enhanced 
by hyperthermia, but the net effect for antisense Glut-5 is not much enhanced by 
hyperthermia; (4) hyperthermia at 43°C for 5 hours and then incubated at 37。C for 
65 hours exerts drastic chronic antiproliferative effect. 
From the results in this chapter, we found that the combined effects of 
hyperthermia and antisense Glut-1 or Glut-5 were additive. The net effect of 
antisense Glut-1 is enhanced by hyperthermia under the present experimental 
1 6 1 
conditions. Since, tumor cells undergo rapid and continuous growth and the 
normal cells do not, mild hyperthermia such as 43°C for 5 hours in this 
experiment can have lower toxic effect on normal cells and produce chronic 
antiproliferative effect on tumor cells. The problem that the duration of response 
by hyperthermia is very short (Vernon C, 1992) might be overcome by antisense 
therapy with or without Lipofectin. 
W e propose that further studies should be performed to verify the additive 
effect of antisense glucose transporters, especially Glut-1, and hyperthermia in 
killing other tumor cells and to study the underlying mechanism. 
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Chapter 7 
Discussion 
This thesis is divided into two parts. The first part investigated the cellular 
uptake of FITC-ODN by flow cytometry in vitro. The aim of the study is to 
investigate the effect of hyperthermia on cellular uptake of antisense 
phosphorothioated oligodeoxynucleotides. Lipofectin-aided transfection, which 
was reported to produce an enhancement in the uptake of antisense molecules in 
vitro, was also studied on MCF-7 cells for the comparison with hyperthermia and 
Lipofectin-aided cellular uptake of O D N . 
The second part investigated the effect of antisense Glut-1 and Glut-5 on 
human breast cancer cell line MCF-7 cells. Hyperthermia alone has antitumor 
effect and the effects of combined treatment between hyperthermia and antisense 
against human glucose transporter 1 and 5 were studied in this project. This is 
because the results ofpart one indicate that hyperthermia can enhance the cellular 
uptake of FITC-ODN on four human cancer cell lines, so combined effect of 
hyperthermia and antisense Glut-1 or Glut-5 on MCF-7 cells was studied and 
compared with that of Lipofectin-aided antisense Glut-1 or Glut-5. 
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Part I: Effect of hyperthermia on the cellular uptake of 
FITC-ODN: 
Cellular uptake of oligodeoxynucleotide is one of the limitations on antisense 
research and therapeutic efficiency. There are several ways to enhance the uptake 
of O D N into the mammalian cells. Microinjection of FITC-labeled O D N into the 
cytoplasm of mammalian cells (Rat2) was shown to be highly localized in the 
nucleus (Fish et. al.,1993). Electroporation was shown to achieve high 
intracellular concentrations of O D N in nearly 100 % of viable cells and the 
transfected ODNs was found to be initially localized to the nucleus and remain 
there for at least 48 hours (Bergan et. al., 1993). Cationic lipids, such as, 
Lipofectin (DOTMA), were commonly used and studied in antisense field. It was 
reported that cationic lipids can improve oligodeoxynucleotide uptake and prevent 
degradation in cultured cells and in human serum (Capaccioli et. al., 1993). 
Hyperthermia is one of the interesting research areas in cancer therapy. It 
involves the use of heat at higher than 37°C temperature, such as 43°C to treat the 
tumor cells for different time periods. Hyperthermia at 43。C increased the cellular 
uptake of doxorubicin in the nuclei of two esophageal squamous cell carcinoma 
cell lines, TE-2 and TE-6 (Kawai et. al., 1997). Using Sprague-Dawley rats as 
experimental model, hyperthermia at 43°C exhibited increased doxorubicin 
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concentrations for all intraabdominal tissues (Jacquet et. al., 1998). This part 
investigated the effect of hyperthermia at 43°C on cellular uptake of 
oligodeoxynucleotide. The enhanced cellular uptake and cellular distribution were 
also compared with Lipofectin-aided cellular uptake of the same 
oligodeoxynucleotide. 
W e have found the following: (1) Hyperthermia at 43°C for 15 hours can 
enhance the oligodeoxynucleotide uptake, by 3-fold on average, on MCF-7 cells 
with 8 ^iM FITC-ODN in serum free RPMI medium. (2) The hyperthermia-
enhanced uptake was incubation time and oligonucleotide concentrations 
dependent. (3) When the effects of hyperthermia on FITC-ODN uptake were 
studied on HepG-2, MDA-MB-231 and Caco-2, hyperthermia exhibited similar 
enhancement in these cells similar to that in MCF-7 cells. (4) By confocal 
microscopy, it was proved that the FITC-ODN was delivered into the cells by 
hyperthermia and Lipofectin, not just adhering on the cell surface. From the 
confocal images of hyperthermia and 37°C control, it is probable that the O D N 
was uptaken through endocytotic pathway as the fluorescence was concentrated in 
some regions at the cytoplasm when compared with the Lipofectin-aided sample, 
which is widely distributed at the cytoplasm. (5) For Lipofectin-aided 
transfection, its effect was dependent on O D N to Lipofectin w/w ratios, 
oligodeoxynucleotide concentrations and transfection time. These three factors 
should be considered in optimizing the transfection effectiveness. (6) Both 
hyperthermia and high concentration of Lipofectin alone have cytotoxic effect on 
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MCF-7 cells under the present experimental conditions. 
Comparing the effects of hyperthermia and Lipofectin on cellular O D N 
uptake in MCF-7 cells, we conclude that although Lipofectin is more potent than 
hyperthermia in fold-enhancement of O D N uptake on average, the transfection 
efficiency as expressed in the peak widths of flow cytometrial curves is not as 
high as hyperthermia because the peaks are much sharper in hyperthermia than 
Lipofectin (from figures 3.1 and 4.1). It is suspected that the Lipofectin-aided 
O D N uptake on cell culture systems may not evenly be transfected as some cells 
may acquire more antisense O D N than others. This may induce some errors in 
comparison of antisense effects as the less-transfected cells may overgrow and 
cover up some extent of antisense effects against cell growth. Moreover, high 
concentration of Lipofectin alone is also cytotoxic in some extents and optimal 
concentrations should be used. 
Under the present experimental conditions, we observed that hyperthermia 
itself kills some percentage of cells by long incubation time, such as, about 45 % 
of MCF-7 cells were killed after hyperthermia at 43°C for 15 hours. This may 
provide important implication in proposed combined treatment of antisense and 
hyperthermia in human cancer therapy. Since hyperthermia can enhance O D N 
uptake in tumor cells, such as MCF-7 cells, and both H T and antisense method 
have antitumor effect alone. Moreover, hyperthermia can also be used in 
combined with other antisense ODN, such as antisense of oncogenes in tumor 
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treatment. This enhancement of O D N uptake by hyperthermia should not be 
limited to MCF-7 cells and antisense Glut. W e have found that hyperthermia 
enhanced the cellular uptake ofFITC-ODN on other human cancer cell lines, such 
as MDA-MB-231, HepG-2 and Caco-2, each with about 2 to 3 fold enhancement 
when compared with control. 
It may be interesting if we could further improve the experimental condition 
to reduce the incubation time by varying the temperature or other parameters, 
such as, oligonucleotide concentrations. 
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Part II: The effect of combined treatment between 
hyperthermia and antisense Glut-1 or Glut-5 on MCF-7 
cells compared with Lipofectin_aided effect: 
In part one, we found that hyperthermia can enhance the uptake of FITC-
O D N on MCF-7 cells. Because the anti-tumor effect of hyperthermia is always 
very short, it was therefore suggested that the combination between hyperthermia 
and chemotherapy or radiation could be applied in cancer therapy. Since antisense 
is a new concept for cancer therapy with potential, it is interesting to study the 
combined treatment of hyperthermia and antisense O D N so as to provide 
alternative combined treatments involving hyperthermia. 
In this part, we conclude that (1) Hyperthermia at 43。C for 5 hours exhibited 
chronic antiproliferative effect when cells were further incubated at 37°C for 65 
hours. (2) Antisense Glut-1 and Glut-5 exhibited antiproliferative effect on cell 
line MCF-7, in the presence or absence of Lipofectin. (3) The effect of antisense 
Glut-1 was more potent than that of antisense Glut-5. (4) Antisense Glut-1 and 
Glut-5 exerted higher antiproliferative effect than that of sense control. (5) The 
effect of combined treatment between antisense Glut-1 and Glut-5 was partially 
additive. (6) The effect of combined treatments between hyperthermia and 
antisense Glut-1 or Glut-5 were both additive. (7) The net effect of antisense Glut-
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1 was enhanced by hyperthermia, but the net effect of antisense Glut-5 was not 
enhanced as much as that of antisense Glut-1 by hyperthermia. (8) Lipofectin-
aided transfection enhanced the potency ofboth antisense Glut-1 and Glut-5. This 
may be due to the fact that uptake of antisense O D N is enhanced by Lipofectin, 
which has been shown in chapter 3. (9) The effects of antisense Glut-1 and 5 with 
Lipofectin were concentration dependent, transfection time dependent and 
antisense to Lipofectin w/w ratio dependent. 
Comparing the effects of hyperthermia and antisense molecules with that of 
Lipofectin and antisense molecules, the optimal conditions of antisense Glut-1 
with Lipofectin, under the present experimental conditions are: 2.5 juM antisense 
concentration with Lipofectin transfection time 15 hours and the antisense to 
Lipofectin ratio is 1 to 4. Under these conditions, the antisense Glut-1 exhibited 
60 % growth suppression and the sense control has only 16 % . For combined 
treatment ofhyperthermia and antisense Glut-1, the antiproliferative effect was 67 
% for 8 ^iM antisense concentration and 5 hours in 43°C. As a result, 
hyperthermia combined with antisense O D N may provide alternative option for 
antisense treatment without Lipofectin. 
For antisense Glut-5 experiments，the growth suppression was 54 % for 
antisense Glut-5 and that for sense control was 28 %, when cells were treated by 
the concentration 2.5 ^iM with Lipofectin transfection time 15 hours and 1:4 
antisense to Lipofectin w/w ratio. For hyperthermia and antisense Glut-5, the 
169 
suppressive effect was 63 % for 8 jiM O D N concentration and 5 hours in 43°C. 
Glucose transporter type-1 has relatively higher affinity towards glucose and 
should be the major glucose transporter on MCF-7 cells. MCF-7 cells express 
Glut-1, Glut-2 and Glut-5 with low level of Glut-4, but without the expression of 
Glut-3 (Zamora-Leon, et. al, 1996). Compared with antisense Glut-1, although 
antisense Glut-5 is less potent in killing MCF-7 cells under several conditions, it 
should be more specific than antisense Glut-1. This is because Glut-1 is expressed 
in almost all tissues and Glut-5 is more tissue-specific. So antisense Glut-5 should 
have less non-specific effect on normal tissues. 
Although most tissues express Glut-1, tumor tissues overexpressed Glut-1 or 
others Gluts. Besides, the glucose demand of tumor cells must be larger than that 
of normal cells, because tumor cells undergo anaerobic glycolysis as well as rapid 
and continuous growth. As a result, the effect of antisense Glut-1 should be larger 
on tumor cells than normal cells. So antisense Glut-1 also has its important value 
in antitumor research. 
Most antisense research are targeted at oncogenes for antitumor effect. In this 
project，we have studied the antitumor effect of antisense on glucose transporters 
because they are over-expressed in tumor cells. W e found that apart from 
antisense against oncogenes, antisense against glucose transporters can also 
produce antiproliferative effect on tumor cells in a specific manner. This is 
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because both oncogenes and glucose transporters are involved in tumor 
development and growth. So, our finding may provide a novel direction in 
antisense strategies for cancer treatment. 
In this chapter, we have discussed that hyperthermia can increase the cellular 
uptake of O D N and antisense strategy against glucose transporter gene has 
antiproliferative effect on tumor cells MCF-7. Lipofectin and hyperthermia can be 
used to enhance the potency of antisense effect. W e have also suggested that the 
combined treatment of hyperthermia and antisense may provide another strategy 
in cancer therapy. Further research in combined effect of H T and antisense should 
be carried out in vitro or in vivo. Hopefully, the finding could be developed into 
human clinical application. 
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The following research directions are suggested for future studies: 
1) Selection of other target regions along the m R N A sequence for antisense 
against glucose transporters: 
In this thesis, the antisense Glut-1 and Glut-5 were targeted around the start 
codon region of the m R N A sequences (Chan et. al., 1999). There may be other 
potential regions for the antisense to target. So for future works, selection of other 
regions can be considered and they can be selected basing on the results of 
Northem blot analysis or Westem blot analysis or by RT-PCR. It is to test the 
inhibition of gene expression by antisense sequences. 
2) RT-PCR or Northem blot analysis for m R N A level: 
RT-PCR or Northem blot analysis can be carried out in the future to test the 
m R N A levels of Glut-1 and Glut-5 after the treatment of antisense techniques, 
although the cell assay provides the functional measurement of the 
antiproliferative effects of antisense Glut-1 and Glut-5 on MCF-7 cells in vitro. 
RT-PCR or Northem blot analysis can provide envidence on antisense 
mechanism. 
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3) Westem blot analysis for protein expression: 
Westem blot analysis is used to measure the protein level. It can be carried 
out in the future to confirm the inhibition of protein expression by the antisense 
method. This method involves antibodies against human glucose transporters 
which can probe the gene expression in protein level after the treatment of 
antisense Glut-1 or Glut-5. 
Together with RT-PCR or Northern blot analysis data, Westem blot data can 
provide us the information required for antisense mechanism. 
4) Combined treatment of antisense Gluts with chemotherapy: 
This is known that multi-drug resistance (MDR) may involve p-glycoprotein 
and p-glycoprotein requires chemical energy from the oxidation of glucose. As a 
result, it is interesting to investigate the effect of antisense Glut on MDR-cell lines 
so as to reverse the M D R phenomenon, because the inhibition of glucose 
transporter gene expression by antisense method could cause the MDR-cells to 
have insufficient glucose supply. The effect of combined treatment between 
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